{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T09:50:46Z","timestamp":1776505846106,"version":"3.51.2"},"reference-count":579,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T00:00:00Z","timestamp":1567209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,7]]},"DOI":"10.1093\/eurheartj\/ehz486","type":"journal-article","created":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T06:34:44Z","timestamp":1567233284000},"page":"255-323","source":"Crossref","is-referenced-by-count":3354,"title":["2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD"],"prefix":"10.1093","volume":"41","author":[{"given":"Francesco","family":"Cosentino","sequence":"first","affiliation":[]},{"given":"Peter J","family":"Grant","sequence":"first","affiliation":[]},{"given":"Victor","family":"Aboyans","sequence":"first","affiliation":[]},{"given":"Clifford J","family":"Bailey","sequence":"first","affiliation":[]},{"given":"Antonio","family":"Ceriello","sequence":"first","affiliation":[]},{"given":"Victoria","family":"Delgado","sequence":"first","affiliation":[]},{"given":"Massimo","family":"Federici","sequence":"first","affiliation":[]},{"given":"Gerasimos","family":"Filippatos","sequence":"first","affiliation":[]},{"given":"Diederick E","family":"Grobbee","sequence":"first","affiliation":[]},{"given":"Tina Birgitte","family":"Hansen","sequence":"first","affiliation":[]},{"given":"Heikki V","family":"Huikuri","sequence":"first","affiliation":[]},{"given":"Isabelle","family":"Johansson","sequence":"first","affiliation":[]},{"given":"Peter","family":"J\u00fcni","sequence":"first","affiliation":[]},{"given":"Maddalena","family":"Lettino","sequence":"first","affiliation":[]},{"given":"Nikolaus","family":"Marx","sequence":"first","affiliation":[]},{"given":"Linda G","family":"Mellbin","sequence":"first","affiliation":[]},{"given":"Carl J","family":"\u00d6stgren","sequence":"first","affiliation":[]},{"given":"Bianca","family":"Rocca","sequence":"first","affiliation":[]},{"given":"Marco","family":"Roffi","sequence":"first","affiliation":[]},{"given":"Naveed","family":"Sattar","sequence":"first","affiliation":[]},{"given":"Petar M","family":"Seferovi\u0107","sequence":"first","affiliation":[]},{"given":"Miguel","family":"Sousa-Uva","sequence":"first","affiliation":[]},{"given":"Paul","family":"Valensi","sequence":"first","affiliation":[]},{"given":"David C","family":"Wheeler","sequence":"first","affiliation":[]},{"name":"ESC Scientific Document Group","sequence":"additional","affiliation":[]},{"given":"Massimo Francesco","family":"Piepoli","sequence":"additional","affiliation":[]},{"given":"K\u00e5re I","family":"Birkeland","sequence":"additional","affiliation":[]},{"given":"Stamatis","family":"Adamopoulos","sequence":"additional","affiliation":[]},{"given":"Ramzi","family":"Ajjan","sequence":"additional","affiliation":[]},{"given":"Angelo","family":"Avogaro","sequence":"additional","affiliation":[]},{"given":"Colin","family":"Baigent","sequence":"additional","affiliation":[]},{"given":"Marianne","family":"Brodmann","sequence":"additional","affiliation":[]},{"given":"H\u00e9ctor","family":"Bueno","sequence":"additional","affiliation":[]},{"given":"Claudio","family":"Ceconi","sequence":"additional","affiliation":[]},{"given":"Ovidiu","family":"Chioncel","sequence":"additional","affiliation":[]},{"given":"Andrew","family":"Coats","sequence":"additional","affiliation":[]},{"given":"Jean-Philippe","family":"Collet","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Collins","sequence":"additional","affiliation":[]},{"given":"Bernard","family":"Cosyns","sequence":"additional","affiliation":[]},{"given":"Carlo","family":"Di Mario","sequence":"additional","affiliation":[]},{"given":"Miles","family":"Fisher","sequence":"additional","affiliation":[]},{"given":"Donna","family":"Fitzsimons","sequence":"additional","affiliation":[]},{"given":"Sigrun","family":"Halvorsen","sequence":"additional","affiliation":[]},{"given":"Dominique","family":"Hansen","sequence":"additional","affiliation":[]},{"given":"Arno","family":"Hoes","sequence":"additional","affiliation":[]},{"given":"Richard I G","family":"Holt","sequence":"additional","affiliation":[]},{"given":"Philip","family":"Home","sequence":"additional","affiliation":[]},{"given":"Hugo A","family":"Katus","sequence":"additional","affiliation":[]},{"given":"Kamlesh","family":"Khunti","sequence":"additional","affiliation":[]},{"given":"Michel","family":"Komajda","sequence":"additional","affiliation":[]},{"given":"Ekaterini","family":"Lambrinou","sequence":"additional","affiliation":[]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[]},{"given":"Basil S","family":"Lewis","sequence":"additional","affiliation":[]},{"given":"Cecilia","family":"Linde","sequence":"additional","affiliation":[]},{"given":"Roberto","family":"Lorusso","sequence":"additional","affiliation":[]},{"given":"Fran\u00e7ois","family":"Mach","sequence":"additional","affiliation":[]},{"given":"Christian","family":"Mueller","sequence":"additional","affiliation":[]},{"given":"Franz-Josef","family":"Neumann","sequence":"additional","affiliation":[]},{"given":"Frederik","family":"Persson","sequence":"additional","affiliation":[]},{"given":"Steffen E","family":"Petersen","sequence":"additional","affiliation":[]},{"given":"Anna Sonia","family":"Petronio","sequence":"additional","affiliation":[]},{"given":"Dimitrios J","family":"Richter","sequence":"additional","affiliation":[]},{"given":"Giuseppe M C","family":"Rosano","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[]},{"given":"Lars","family":"Ryd\u00e9n","sequence":"additional","affiliation":[]},{"given":"Evgeny","family":"Shlyakhto","sequence":"additional","affiliation":[]},{"given":"Iain A","family":"Simpson","sequence":"additional","affiliation":[]},{"given":"Rhian M","family":"Touyz","sequence":"additional","affiliation":[]},{"given":"William","family":"Wijns","sequence":"additional","affiliation":[]},{"given":"Matthias","family":"Wilhelm","sequence":"additional","affiliation":[]},{"given":"Bryan","family":"Williams","sequence":"additional","affiliation":[]},{"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[]},{"given":"Clifford J","family":"Bailey","sequence":"additional","affiliation":[]},{"given":"Antonio","family":"Ceriello","sequence":"additional","affiliation":[]},{"given":"Victoria","family":"Delgado","sequence":"additional","affiliation":[]},{"given":"Massimo","family":"Federici","sequence":"additional","affiliation":[]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[]},{"given":"Diederick E","family":"Grobbee","sequence":"additional","affiliation":[]},{"given":"Tina Birgitte","family":"Hansen","sequence":"additional","affiliation":[]},{"given":"Heikki V","family":"Huikuri","sequence":"additional","affiliation":[]},{"given":"Isabelle","family":"Johansson","sequence":"additional","affiliation":[]},{"given":"Peter","family":"J\u00fcni","sequence":"additional","affiliation":[]},{"given":"Maddalena","family":"Lettino","sequence":"additional","affiliation":[]},{"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[]},{"given":"Linda G","family":"Mellbin","sequence":"additional","affiliation":[]},{"given":"Carl J","family":"\u00d6stgren","sequence":"additional","affiliation":[]},{"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[]},{"given":"Marco","family":"Roffi","sequence":"additional","affiliation":[]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[]},{"given":"Petar M","family":"Seferovi\u0107","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Sousa-Uva","sequence":"additional","affiliation":[]},{"given":"Paul","family":"Valensi","sequence":"additional","affiliation":[]},{"given":"David C","family":"Wheeler","sequence":"additional","affiliation":[]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[]},{"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[]},{"given":"Colin","family":"Baigent","sequence":"additional","affiliation":[]},{"given":"Jean-Philippe","family":"Collet","sequence":"additional","affiliation":[]},{"given":"Veronica","family":"Dean","sequence":"additional","affiliation":[]},{"given":"Victoria","family":"Delgado","sequence":"additional","affiliation":[]},{"given":"Donna","family":"Fitzsimons","sequence":"additional","affiliation":[]},{"given":"Chris P","family":"Gale","sequence":"additional","affiliation":[]},{"given":"Diederick E","family":"Grobbee","sequence":"additional","affiliation":[]},{"given":"Sigrun","family":"Halvorsen","sequence":"additional","affiliation":[]},{"given":"Gerhard","family":"Hindricks","sequence":"additional","affiliation":[]},{"given":"Bernard","family":"Iung","sequence":"additional","affiliation":[]},{"given":"Peter","family":"J\u00fcni","sequence":"additional","affiliation":[]},{"given":"Hugo A","family":"Katus","sequence":"additional","affiliation":[]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[]},{"given":"Christophe","family":"Leclercq","sequence":"additional","affiliation":[]},{"given":"Maddalena","family":"Lettino","sequence":"additional","affiliation":[]},{"given":"Basil S","family":"Lewis","sequence":"additional","affiliation":[]},{"given":"Bela","family":"Merkely","sequence":"additional","affiliation":[]},{"given":"Christian","family":"Mueller","sequence":"additional","affiliation":[]},{"given":"Steffen E","family":"Petersen","sequence":"additional","affiliation":[]},{"given":"Anna Sonia","family":"Petronio","sequence":"additional","affiliation":[]},{"given":"Dimitrios J","family":"Richter","sequence":"additional","affiliation":[]},{"given":"Marco","family":"Roffi","sequence":"additional","affiliation":[]},{"given":"Evgeny","family":"Shlyakhto","sequence":"additional","affiliation":[]},{"given":"Iain A","family":"Simpson","sequence":"additional","affiliation":[]},{"given":"Miguel","family":"Sousa-Uva","sequence":"additional","affiliation":[]},{"given":"Rhian M","family":"Touyz","sequence":"additional","affiliation":[]},{"given":"Parounak H","family":"Zelveian","sequence":"additional","affiliation":[]},{"given":"Daniel","family":"Scherr","sequence":"additional","affiliation":[]},{"given":"Tofig","family":"Jahangirov","sequence":"additional","affiliation":[]},{"given":"Irina","family":"Lazareva","sequence":"additional","affiliation":[]},{"given":"Bharati","family":"Shivalkar","sequence":"additional","affiliation":[]},{"given":"Nabil","family":"Naser","sequence":"additional","affiliation":[]},{"given":"Ivan","family":"Gruev","sequence":"additional","affiliation":[]},{"given":"Davor","family":"Milicic","sequence":"additional","affiliation":[]},{"given":"Petros M","family":"Petrou","sequence":"additional","affiliation":[]},{"given":"Ale\u0161","family":"Linhart","sequence":"additional","affiliation":[]},{"given":"Per","family":"Hildebrandt","sequence":"additional","affiliation":[]},{"given":"Hosam","family":"Hasan-Ali","sequence":"additional","affiliation":[]},{"given":"Toomas","family":"Marandi","sequence":"additional","affiliation":[]},{"given":"Seppo","family":"Lehto","sequence":"additional","affiliation":[]},{"given":"Jacques","family":"Mansourati","sequence":"additional","affiliation":[]},{"given":"Ramaz","family":"Kurashvili","sequence":"additional","affiliation":[]},{"given":"Gerasimos","family":"Siasos","sequence":"additional","affiliation":[]},{"given":"Csaba","family":"Lengyel","sequence":"additional","affiliation":[]},{"given":"Inga S","family":"Thrainsdottir","sequence":"additional","affiliation":[]},{"given":"Doron","family":"Aronson","sequence":"additional","affiliation":[]},{"given":"Andrea","family":"Di Lenarda","sequence":"additional","affiliation":[]},{"given":"Aigul","family":"Raissova","sequence":"additional","affiliation":[]},{"given":"Pranvera","family":"Ibrahimi","sequence":"additional","affiliation":[]},{"given":"Saamai","family":"Abilova","sequence":"additional","affiliation":[]},{"given":"Karlis","family":"Trusinskis","sequence":"additional","affiliation":[]},{"given":"Georges","family":"Saade","sequence":"additional","affiliation":[]},{"given":"Hisham","family":"Benlamin","sequence":"additional","affiliation":[]},{"given":"Zaneta","family":"Petrulioniene","sequence":"additional","affiliation":[]},{"given":"Cristiana","family":"Banu","sequence":"additional","affiliation":[]},{"given":"Caroline Jane","family":"Magri","sequence":"additional","affiliation":[]},{"given":"Lilia","family":"David","sequence":"additional","affiliation":[]},{"given":"Aneta","family":"Boskovic","sequence":"additional","affiliation":[]},{"given":"Mohamed","family":"Alami","sequence":"additional","affiliation":[]},{"given":"An Ho","family":"Liem","sequence":"additional","affiliation":[]},{"given":"Marijan","family":"Bosevski","sequence":"additional","affiliation":[]},{"given":"Gard Frodahl Tveitevaag","family":"Svingen","sequence":"additional","affiliation":[]},{"given":"Marianna","family":"Janion","sequence":"additional","affiliation":[]},{"given":"Cristina","family":"Gavina","sequence":"additional","affiliation":[]},{"given":"Dragos","family":"Vinereanu","sequence":"additional","affiliation":[]},{"given":"Sergey","family":"Nedogoda","sequence":"additional","affiliation":[]},{"given":"Tatiana","family":"Mancini","sequence":"additional","affiliation":[]},{"given":"Marina Deljanin","family":"Ilic","sequence":"additional","affiliation":[]},{"given":"Lubomira","family":"Fabryova","sequence":"additional","affiliation":[]},{"given":"Zlatko","family":"Fras","sequence":"additional","affiliation":[]},{"given":"Manuel F","family":"Jim\u00e9nez-Navarro","sequence":"additional","affiliation":[]},{"given":"Anna","family":"Norhammar","sequence":"additional","affiliation":[]},{"given":"Roger","family":"Lehmann","sequence":"additional","affiliation":[]},{"given":"Mohamed Sami","family":"Mourali","sequence":"additional","affiliation":[]},{"given":"Dilek","family":"Ural","sequence":"additional","affiliation":[]},{"given":"Elena","family":"Nesukay","sequence":"additional","affiliation":[]},{"given":"Tahseen Ahmad","family":"Chowdhury","sequence":"additional","affiliation":[]}],"member":"286","published-online":{"date-parts":[[2019,8,31]]},"reference":[{"key":"2020042304154226900_ehz486-B1"},{"key":"2020042304154226900_ehz486-B2","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.2337\/dc14-S081","article-title":"American Diabetes Association. Diagnosis and classification of diabetes mellitus","volume":"37","year":"2014","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B3"},{"key":"2020042304154226900_ehz486-B4"},{"key":"2020042304154226900_ehz486-B5","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2337\/dc19-S002","article-title":"2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B6","doi-asserted-by":"crossref","first-page":"i6538","DOI":"10.1136\/bmj.i6538","article-title":"Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions","volume":"356","author":"Barry","year":"2017","journal-title":"BMJ"},{"key":"2020042304154226900_ehz486-B7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.diabet.2010.02.004","article-title":"A large proportion of prediabetes and diabetes goes undiagnosed when only fasting plasma glucose and\/or HbA1c are measured in overweight or obese patients","volume":"36","author":"Cosson","year":"2010","journal-title":"Diabetes Metab"},{"key":"2020042304154226900_ehz486-B8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12933-018-0665-4","article-title":"Undetected dysglycaemia common in primary care patients treated for hypertension and\/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology","volume":"17","author":"Shahim","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"2020042304154226900_ehz486-B9","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/S0140-6736(02)09089-X","article-title":"Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study","volume":"359","author":"Norhammar","year":"2002","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/hrt.2005.086975","article-title":"Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart","volume":"93","author":"Bartnik","year":"2007","journal-title":"Heart"},{"key":"2020042304154226900_ehz486-B11","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/eurheartj\/ehv008","article-title":"Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV--a survey from the European Society of Cardiology","volume":"36","author":"Gyberg","year":"2015","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B12","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1007\/s00125-011-2253-y","article-title":"Oral glucose tolerance test and HbA1c for diagnosis of diabetes in patients undergoing coronary angiography: [corrected] the Silent Diabetes Study","volume":"54","author":"Doerr","year":"2011","journal-title":"Diabetologia"},{"key":"2020042304154226900_ehz486-B13","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1161\/CIRCULATIONAHA.108.780999","article-title":"Metabolic management of acute myocardial infarction comes to the fore and extends beyond control of hyperglycemia","volume":"117","author":"Opie","year":"2008","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B14","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.2337\/diacare.26.10.2770","article-title":"Diabetes, insulin resistance, and the metabolic syndrome in patients with acute myocardial infarction without previously known diabetes","volume":"26","author":"Tenerz","year":"2003","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B15","doi-asserted-by":"crossref","first-page":"e4624","DOI":"10.1136\/bmj.e4624","article-title":"Risk identification and interventions to prevent type 2 diabetes in adults at high risk: summary of NICE guidance","volume":"345","author":"Chatterton","year":"2012","journal-title":"BMJ"},{"key":"2020042304154226900_ehz486-B16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1479164114551746","article-title":"Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort","volume":"12","author":"Ritsinger","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"2020042304154226900_ehz486-B17","doi-asserted-by":"crossref","first-page":"e017184","DOI":"10.1136\/bmjopen-2017-017184","article-title":"Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes","volume":"7","author":"Roberts","year":"2017","journal-title":"BMJ Open"},{"key":"2020042304154226900_ehz486-B18","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2337\/dc17-0245","article-title":"The prognostic value of fasting plasma glucose, two-hour postload glucose, and HbA1c in patients with coronary artery disease: a report from EUROASPIRE IV: a survey from the European Society of Cardiology","volume":"40","author":"Shahim","year":"2017","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B19","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2337\/dc18-S002","article-title":"2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B20","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.2215\/CJN.02870316","article-title":"Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: the DCCT\/EDIC study","volume":"11","author":"de Boer","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2020042304154226900_ehz486-B21","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jacc.2013.05.069","article-title":"PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial","volume":"62","author":"Huelsmann","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.atherosclerosis.2017.07.009","article-title":"Comparison of non-traditional biomarkers, and combinations of biomarkers, for vascular risk prediction in people with type 2 diabetes: the Edinburgh Type 2 Diabetes study","volume":"264","author":"Price","year":"2017","journal-title":"Atherosclerosis"},{"key":"2020042304154226900_ehz486-B23","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(18)31506-X","article-title":"Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study","volume":"392","author":"Rawshani","year":"2018","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B25","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1056\/NEJMoa1504347","article-title":"Excess mortality among persons with type 2 diabetes","volume":"373","author":"Tancredi","year":"2015","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B26","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1161\/CIRCULATIONAHA.118.037885","article-title":"Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks","volume":"139","author":"Sattar","year":"2019","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B27","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B28","doi-asserted-by":"crossref","first-page":"876","DOI":"10.2337\/dc17-2352","article-title":"Characteristics and prognosis in women and men with type 1 diabetes undergoing coronary angiography: a nationwide registry report","volume":"41","author":"Ritsinger","year":"2018","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B29","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S2213-8587(18)30079-2","article-title":"Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies","volume":"6","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2020042304154226900_ehz486-B30","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2337\/dc17-2530","article-title":"Risk of cardiovascular disease and death in individuals with prediabetes defined by different criteria: the Whitehall II study","volume":"41","author":"Vistisen","year":"2018","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B31","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1056\/NEJMoa1107477","article-title":"C-reactive protein, fibrinogen, and cardiovascular disease prediction","volume":"367","author":"Kaptoge","year":"2012","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ahj.2015.12.015","article-title":"High-sensitive troponin T is associated with all-cause and cardiovascular mortality in stable outpatients with type 2 diabetes (ZODIAC-37)","volume":"174","author":"Hendriks","year":"2016","journal-title":"Am Heart J"},{"key":"2020042304154226900_ehz486-B33","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.kint.2017.04.018","article-title":"Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy","volume":"92","author":"Galsgaard","year":"2017","journal-title":"Kidney Int"},{"key":"2020042304154226900_ehz486-B34","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1093\/eurheartj\/ehn334","article-title":"NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus","volume":"29","author":"Huelsmann","year":"2008","journal-title":"Eur Heart J"},{"issue":"10","key":"2020042304154226900_ehz486-B35","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1371\/journal.pmed.0050207","article-title":"The relationship between proteinuria and coronary risk: a systematic review and meta-analysis","volume":"5","author":"Perkovic","year":"2008","journal-title":"PLoS Med"},{"key":"2020042304154226900_ehz486-B36","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)07368-1","article-title":"Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study","volume":"353","author":"Gaede","year":"1999","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B37","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00125-016-4065-6","article-title":"Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial","volume":"59","author":"Gaede","year":"2016","journal-title":"Diabetologia"},{"key":"2020042304154226900_ehz486-B38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.acvd.2010.11.013","article-title":"Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: a review of the literature","volume":"104","author":"Valensi","year":"2011","journal-title":"Arch Cardiovasc Dis"},{"key":"2020042304154226900_ehz486-B39","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ijcard.2015.01.017","article-title":"Silent coronary artery disease and incidence of cardiovascular and mortality events at different levels of glucose regulation; results of greater than a decade follow-up","volume":"182","author":"Hadaegh","year":"2015","journal-title":"Int J Cardiol"},{"key":"2020042304154226900_ehz486-B40","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1093\/eurheartj\/ehq368","article-title":"Resting heart rate in patients with stable coronary artery disease and diabetes: a report from the euro heart survey on diabetes and the heart","volume":"31","author":"Anselmino","year":"2010","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B41","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s00125-006-0483-1","article-title":"QTc interval and resting heart rate as long-term predictors of mortality in type 1 and type 2 diabetes mellitus: a 23-year follow-up","volume":"50","author":"Stettler","year":"2007","journal-title":"Diabetologia"},{"key":"2020042304154226900_ehz486-B42","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.2337\/diabetes.51.12.3524","article-title":"Lower heart rate variability is associated with the development of coronary heart disease in individuals with diabetes: the atherosclerosis risk in communities (ARIC) study","volume":"51","author":"Liao","year":"2002","journal-title":". Diabetes"},{"key":"2020042304154226900_ehz486-B43","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.2337\/dc10-0125","article-title":"Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial","volume":"33","author":"Pop-Busui","year":"2010","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B44","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.atherosclerosis.2013.01.011","article-title":"Incremental prognostic value of stress myocardial perfusion imaging in asymptomatic diabetic patients","volume":"227","author":"Acampa","year":"2013","journal-title":"Atherosclerosis"},{"key":"2020042304154226900_ehz486-B45","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/eurheartj\/ehi808","article-title":"Risk stratification in uncomplicated type 2 diabetes: prospective evaluation of the combined use of coronary artery calcium imaging and selective myocardial perfusion scintigraphy","volume":"27","author":"Anand","year":"2006","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jacc.2005.10.008","article-title":"Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus","volume":"47","author":"Scognamiglio","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B47","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.2337\/diacare.27.8.1954","article-title":"Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study","volume":"27","author":"Wackers","year":"2004","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B48","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jcmg.2014.07.010","article-title":"Progression to overt or silent CAD in asymptomatic patients with diabetes mellitus at high coronary risk: main findings of the prospective multicenter BARDOT trial with a pilot randomized treatment substudy","volume":"7","author":"Zellweger","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"2020042304154226900_ehz486-B49","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1378\/chest.119.5.1576","article-title":"Clinical utility of the exercise ECG in patients with diabetes and chest pain","volume":"119","author":"Lee","year":"2001","journal-title":"Chest"},{"key":"2020042304154226900_ehz486-B50","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1464-5491.2004.01157.x","article-title":"Detecting silent coronary stenoses and stratifying cardiac risk in patients with diabetes: ECG stress test or exercise myocardial scintigraphy?","volume":"21","author":"Cosson","year":"2004","journal-title":"Diabet Med"},{"key":"2020042304154226900_ehz486-B51","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1161\/01.CIR.103.21.2566","article-title":"Prediction of mortality by exercise echocardiography: a strategy for combination with the duke treadmill score","volume":"103","author":"Marwick","year":"2001","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B52","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.2337\/diacare.28.11.2722","article-title":"Predictive value of silent myocardial ischemia for cardiac events in diabetic patients: influence of age in a French multicenter study","volume":"28","author":"Valensi","year":"2005","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B53","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.jacc.2017.07.792","article-title":"Clinical implications of echocardiographic phenotypes of patients with diabetes mellitus","volume":"70","author":"Ernande","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B54","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jacc.2009.12.003","article-title":"The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study","volume":"55","author":"From","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B55","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1161\/CIRCIMAGING.111.963587","article-title":"Association of imaging markers of myocardial fibrosis with metabolic and functional disturbances in early diabetic cardiomyopathy","volume":"4","author":"Jellis","year":"2011","journal-title":"Circ Cardiovasc Imaging"},{"key":"2020042304154226900_ehz486-B56","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.amjcard.2009.06.063","article-title":"Findings from left ventricular strain and strain rate imaging in asymptomatic patients with type 2 diabetes mellitus","volume":"104","author":"Ng","year":"2009","journal-title":"Am J Cardiol"},{"key":"2020042304154226900_ehz486-B57","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.diabet.2010.12.006","article-title":"Transthoracic echocardiographic abnormalities in asymptomatic diabetic patients: association with microalbuminuria and silent coronary artery disease","volume":"37","author":"Nguyen","year":"2011","journal-title":"Diabetes Metab"},{"key":"2020042304154226900_ehz486-B58","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1161\/CIRCULATIONAHA.110.955542","article-title":"Myocardial steatosis and biventricular strain and strain rate imaging in patients with type 2 diabetes mellitus","volume":"122","author":"Ng","year":"2010","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCIMAGING.111.965608","article-title":"Association between diffuse myocardial fibrosis by cardiac magnetic resonance contrast-enhanced T-1 mapping and subclinical myocardial dysfunction in diabetic patients: a pilot study","volume":"5","author":"Ng","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"2020042304154226900_ehz486-B60","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.5551\/jat.43141","article-title":"Clinical utility of carotid ultrasonography in the prediction of cardiovascular events in patients with diabetes: a combined analysis of data obtained in five longitudinal studies","volume":"25","author":"Katakami","year":"2018","journal-title":"J\u00a0Atheroscler Thromb"},{"key":"2020042304154226900_ehz486-B61","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1001\/jama.2016.17020","article-title":"Prevalence and prognostic implications of coronary artery calcification in low-risk women: a meta-analysis","volume":"316","author":"Kavousi","year":"2016","journal-title":"JAMA"},{"key":"2020042304154226900_ehz486-B62","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(12)60441-3","article-title":"Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data","volume":"379","author":"Lorenz","year":"2012","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B63","doi-asserted-by":"crossref","first-page":"e003528","DOI":"10.1161\/CIRCIMAGING.115.003528","article-title":"Absence of coronary artery calcium identifies asymptomatic diabetic individuals at low near-term but not long-term risk of mortality: a 15-year follow-up study of 9715 patients","volume":"9","author":"Valenti","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"2020042304154226900_ehz486-B64","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1745-6215-12-23","article-title":"Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening","volume":"12","author":"Li\u00e8vre","year":"2011","journal-title":"Trials"},{"key":"2020042304154226900_ehz486-B65","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/ehjci\/jey014","article-title":"Non-invasive screening for coronary artery disease in asymptomatic diabetic patients: a systematic review and meta-analysis of randomised controlled trials","volume":"19","author":"Clerc","year":"2018","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2020042304154226900_ehz486-B66","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2337\/diacare.26.4.1313","article-title":"Prognosis for coronary stenoses in patients with diabetes and silent myocardial ischemia","volume":"26","author":"Cosson","year":"2003","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B67","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1001\/jama.2014.15825","article-title":"Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial","volume":"312","author":"Muhlestein","year":"2014","journal-title":"JAMA"},{"key":"2020042304154226900_ehz486-B68","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1001\/jama.2009.476","article-title":"Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial","volume":"301","author":"Young","year":"2009","journal-title":"JAMA"},{"key":"2020042304154226900_ehz486-B69","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ahj.2004.07.027","article-title":"Risk reduction of cardiac events by screening of unknown asymptomatic coronary artery disease in subjects with type 2 diabetes mellitus at high cardiovascular risk: an open-label randomized pilot study","volume":"149","author":"Faglia","year":"2005","journal-title":"Am Heart J"},{"key":"2020042304154226900_ehz486-B70","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ejim.2015.05.006","article-title":"Does coronary Atherosclerosis Deserve to be Diagnosed earlY in Diabetic patients? The DADDY-D trial. Screening diabetic patients for unknown coronary disease","volume":"26","author":"Turrini","year":"2015","journal-title":"Eur J Intern Med"},{"key":"2020042304154226900_ehz486-B71","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/1479164111431470","article-title":"Gender-based divergence of cardiovascular outcomes in asymptomatic patients with type 2 diabetes: results from the DIAD study","volume":"9","author":"Tandon","year":"2012","journal-title":"Diab Vasc Dis Res"},{"key":"2020042304154226900_ehz486-B72","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/eurheartj\/eht108","article-title":"ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD)","volume":"34","author":"Ryden","year":"2013","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B73","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2337\/dc11-0816","article-title":"Impact of subclinical atherosclerosis on cardiovascular disease events in individuals with metabolic syndrome and diabetes: the multi-ethnic study of atherosclerosis","volume":"34","author":"Malik","year":"2011","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B74","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/jdi.12403","article-title":"Usefulness of carotid plaque (sum and maximum of plaque thickness) in combination with intima-media thickness for the detection of coronary artery disease in asymptomatic patients with diabetes","volume":"7","author":"Akazawa","year":"2016","journal-title":"J\u00a0Diabetes Investig"},{"key":"2020042304154226900_ehz486-B75","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.atherosclerosis.2013.08.015","article-title":"The utility of ultrasonic tissue characterization of carotid plaque in the prediction of cardiovascular events in diabetic patients","volume":"230","author":"Irie","year":"2013","journal-title":"Atherosclerosis"},{"key":"2020042304154226900_ehz486-B76","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.2337\/dc12-0178","article-title":"Associations between the ankle-brachial index and cardiovascular and all-cause mortality are similar in individuals without and with type 2 diabetes: nineteen-year follow-up of a population-based cohort study","volume":"35","author":"Hanssen","year":"2012","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B77","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.2337\/dc15-0327","article-title":"Carotid plaque calcification predicts future cardiovascular events in type 2 diabetes","volume":"38","author":"Vigili de Kreutzenberg","year":"2015","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B78","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1001\/jama.2012.9630","article-title":"Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis","volume":"308","author":"Den Ruijter","year":"2012","journal-title":"JAMA"},{"key":"2020042304154226900_ehz486-B79","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.2337\/dc18-S004","article-title":"4. Lifestyle management: Standards of Medical Care in Diabetes-2018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B80","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.2337\/dc14-S120","article-title":"Nutrition therapy recommendations for the management of adults with diabetes","volume":"37","author":"Evert","year":"2014","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B81","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00125-014-3460-0","article-title":"Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"58","author":"Inzucchi","year":"2015","journal-title":"Diabetologia"},{"key":"2020042304154226900_ehz486-B82","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7326\/M15-0452","article-title":"Combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Preventive Services Task Force","volume":"163","author":"Balk","year":"2015","journal-title":"Ann Intern Med"},{"key":"2020042304154226900_ehz486-B83","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.jand.2017.03.023","article-title":"Academy of Nutrition and Dietetics Nutrition Practice Guideline for Type 1 and Type 2 Diabetes in Adults: nutrition intervention evidence reviews and recommendations","volume":"117","author":"MacLeod","year":"2017","journal-title":"J\u00a0Acad Nutr Diet"},{"key":"2020042304154226900_ehz486-B84","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.2337\/dc17-2222","article-title":"Global diabetes prevention interventions: a systematic review and network meta-analysis of the real-world impact on incidence, weight, and glucose","volume":"41","author":"Galaviz","year":"2018","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B85","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","article-title":"Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance","volume":"344","author":"Tuomilehto","year":"2001","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B86","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S2213-8587(14)70057-9","article-title":"Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study","volume":"2","author":"Li","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2020042304154226900_ehz486-B87","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S2213-8587(19)30093-2","article-title":"Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study","volume":"7","author":"Gong","journal-title":"Lancet Diabetes Endocrinol 2019"},{"key":"2020042304154226900_ehz486-B88","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S2213-8587(15)00291-0","article-title":"Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study","volume":"3","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2020042304154226900_ehz486-B89","doi-asserted-by":"crossref","first-page":"e000259","DOI":"10.1136\/bmjdrc-2016-000259","article-title":"Long-term effect of intensive lifestyle intervention on cardiovascular risk factors in patients with diabetes in real-world clinical practice: a 5-year longitudinal study","volume":"5","author":"Hamdy","year":"2017","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2020042304154226900_ehz486-B90","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jand.2015.02.031","article-title":"Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials","volume":"115","author":"Franz","year":"2015","journal-title":"J\u00a0Acad Nutr Diet"},{"key":"2020042304154226900_ehz486-B91","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa1212914","article-title":"Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes","volume":"369","author":"Wing","year":"2013","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B92","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(17)33102-1","article-title":"Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial","volume":"391","author":"Lean","year":"2018","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B93","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S2213-8587(19)30068-3","article-title":"Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial","volume":"7","author":"Lean","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2020042304154226900_ehz486-B94","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1056\/NEJMoa035622","article-title":"Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery","volume":"351","author":"Sj\u00f6str\u00f6m","year":"2004","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B95","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1001\/jama.2017.20813","article-title":"Lifestyle intervention and medical management with vs without Roux-en-Y gastric bypass and control of hemoglobin A1c, LDL cholesterol, and systolic blood pressure at 5 years in the Diabetes Surgery Study","volume":"319","author":"Ikramuddin","year":"2018","journal-title":"JAMA"},{"key":"2020042304154226900_ehz486-B96","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B97","doi-asserted-by":"crossref","first-page":"e000354","DOI":"10.1136\/bmjdrc-2016-000354","article-title":"Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes","volume":"5","author":"Snorgaard","journal-title":"BMJ Open Diabetes Res Care 2017"},{"key":"2020042304154226900_ehz486-B98","doi-asserted-by":"crossref","first-page":"491","DOI":"10.7326\/M16-0361","article-title":"Effects on health outcomes of a Mediterranean diet with no restriction on fat intake: a systematic review and meta-analysis","volume":"165","author":"Bloomfield","year":"2016","journal-title":"Ann Intern Med"},{"key":"2020042304154226900_ehz486-B99","doi-asserted-by":"crossref","first-page":"1\u2013e","DOI":"10.1161\/CIR.0000000000000510","article-title":"Dietary fats and cardiovascular disease: a Presidential Advisory from the American Heart Association","volume":"136","author":"Sacks","year":"2017","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B100","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/dc11-2216","article-title":"Macronutrients, food groups, and eating patterns in the management of diabetes: a systematic review of the literature, 2010","volume":"35","author":"Wheeler","year":"2012","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B101","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1203859","article-title":"n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia","volume":"367","author":"Bosch","year":"2012","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B102","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n-3 fatty acid supplements in diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B103","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B104","first-page":"721","article-title":"Diets for health: goals and guidelines","volume":"97","author":"Locke","year":"2018","journal-title":"Am Fam Physician"},{"key":"2020042304154226900_ehz486-B105","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(18)30134-X","article-title":"Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies","volume":"391","author":"Wood","year":"2018","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B106","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1007\/s00125-006-0435-9","article-title":"Coffee consumption and risk of total and cardiovascular mortality among patients with type 2 diabetes","volume":"49","author":"Bidel","year":"2006","journal-title":"Diabetologia"},{"key":"2020042304154226900_ehz486-B107","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJM198911233212103","article-title":"The effect on serum cholesterol levels of coffee brewed by filtering or boiling","volume":"321","author":"Bak","year":"1989","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B108","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1001\/archinternmed.2009.439","article-title":"Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis","volume":"169","author":"Huxley","year":"2009","journal-title":"Arch Intern Med"},{"key":"2020042304154226900_ehz486-B109","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/archinternmed.2012.3130","article-title":"Physical activity and mortality in individuals with diabetes mellitus: a prospective study and meta-analysis","volume":"172","author":"Sluik","year":"2012","journal-title":"Arch Intern Med"},{"key":"2020042304154226900_ehz486-B110","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1177\/1741826711430926","article-title":"Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR. Part II","volume":"19","author":"Vanhees","year":"2012","journal-title":"Eur J Prev Cardiol"},{"key":"2020042304154226900_ehz486-B111","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1001\/jama.2011.576","article-title":"Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis","volume":"305","author":"Umpierre","year":"2011","journal-title":"JAMA"},{"key":"2020042304154226900_ehz486-B112","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1001\/jama.2010.1710","article-title":"Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial","volume":"304","author":"Church","year":"2010","journal-title":"JAMA"},{"key":"2020042304154226900_ehz486-B113","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.2337\/dc16-1728","article-title":"Physical activity\/exercise and diabetes: a position statement of the American Diabetes Association","volume":"39","author":"Colberg","year":"2016","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B114","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1001\/jama.298.22.2654","article-title":"Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis","volume":"298","author":"Willi","year":"2007","journal-title":"JAMA"},{"key":"2020042304154226900_ehz486-B115","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(17)30819-X","article-title":"Smoking prevalence and attributable disease burden in 195 countries and territories, 1990-2015: a systematic analysis from the Global Burden of Disease Study 2015","volume":"389","year":"2017","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B116","doi-asserted-by":"crossref","first-page":"e0139907","DOI":"10.1371\/journal.pone.0139907","article-title":"The health effects of passive smoking: an overview of systematic reviews based on observational epidemiological evidence","volume":"10","author":"Cao","year":"2015","journal-title":"PLoS One"},{"key":"2020042304154226900_ehz486-B117","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/eurheartj\/ehu051","article-title":"Effectiveness of a preventive cardiology programme for high CVD risk persistent smokers: the EUROACTION PLUS varenicline trial","volume":"35","author":"Jennings","year":"2014","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B118","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.amjcard.2018.01.017","article-title":"Smoking cessation in patients with acute coronary syndrome","volume":"121","author":"Franck","year":"2018","journal-title":"Am J Cardiol"},{"key":"2020042304154226900_ehz486-B119","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-2796.2012.02532.x","article-title":"Alcohol consumption and risk of type 2 diabetes in European men and women: influence of beverage type and body size The EPIC-InterAct study","volume":"272","author":"Beulens","year":"2012","journal-title":"J\u00a0Intern Med"},{"key":"2020042304154226900_ehz486-B120"},{"key":"2020042304154226900_ehz486-B121","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","article-title":"Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials","volume":"373","author":"Ray","year":"2009","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B122","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","article-title":"Intensive glucose control and macrovascular outcomes in type 2 diabetes","volume":"52","author":"Turnbull","year":"2009","journal-title":"Diabetologia"},{"key":"2020042304154226900_ehz486-B123","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2337\/dc17-1144","article-title":"The legacy effect in type 2 diabetes: impact of early glycemic control on future complications (the Diabetes & Aging Study)","volume":"42","author":"Laiteerapong","year":"2019","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B124","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(98)12131-1","article-title":"Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B125","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.numecd.2008.01.012","article-title":"Guideline for management of postmeal glucose","volume":"18","author":"Ceriello","year":"2008","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2020042304154226900_ehz486-B126","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.2337\/dc18-0548","article-title":"Glycemic variation and cardiovascular risk in the veterans affairs diabetes trial","volume":"41","author":"Zhou","year":"2018","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B127","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2337\/dc08-1671","article-title":"Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial","volume":"32","author":"Raz","year":"2009","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B128","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.2337\/dc10-2375","article-title":"Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting\/premeal glycemia","volume":"34","author":"Raz","year":"2011","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B129","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2213-8587(17)30309-1","article-title":"Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial","volume":"5","author":"Holman","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2020042304154226900_ehz486-B130","doi-asserted-by":"crossref","first-page":"416 e9","DOI":"10.1016\/j.amjmed.2011.07.027","article-title":"Variation of fasting plasma glucose: a predictor of mortality in patients with type 2 diabetes","volume":"125","author":"Lin","year":"2012","journal-title":"Am J Med"},{"key":"2020042304154226900_ehz486-B131","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.2337\/dc14-0199","article-title":"Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial","volume":"37","author":"Hirakawa","year":"2014","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B132","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00125-017-4423-z","article-title":"Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)","volume":"61","author":"Zinman","year":"2018","journal-title":"Diabetologia"},{"key":"2020042304154226900_ehz486-B133","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.metabol.2014.09.006","article-title":"Increased glycemic variability and decrease of the postprandial glucose contribution to HbA1c in obese subjects across the glycemic continuum from normal glycemia to first time diagnosed diabetes","volume":"63","author":"Fysekidis","year":"2014","journal-title":"Metabolism"},{"key":"2020042304154226900_ehz486-B134","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00125-010-1918-2","article-title":"HbA(1)(c) and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study","volume":"54","author":"Borg","year":"2011","journal-title":"Diabetologia"},{"key":"2020042304154226900_ehz486-B135","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(18)30136-0","article-title":"Glycaemic variability in diabetes: clinical and therapeutic implications","volume":"7","author":"Ceriello","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2020042304154226900_ehz486-B136","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.beem.2016.06.004","article-title":"Managing hypoglycaemia","volume":"30","author":"Iqbal","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2020042304154226900_ehz486-B137","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/hrt.2008.152835","article-title":"Prognostic implications of hypoglycaemic episodes during hospitalisation for myocardial infarction in patients with type 2 diabetes: a report from the DIGAMI 2 trial","volume":"95","author":"Mellbin","year":"2009","journal-title":"Heart"},{"key":"2020042304154226900_ehz486-B138","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B139","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1093\/eurheartj\/eht332","article-title":"Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial","volume":"34","author":"Mellbin","year":"2013","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B140","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00125-017-4422-0","article-title":"DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality","volume":"61","author":"Pieber","year":"2018","journal-title":"Diabetologia"},{"key":"2020042304154226900_ehz486-B141","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.2337\/dc13-0092","article-title":"Intensive structured self-monitoring of blood glucose and glycemic control in noninsulin-treated type 2 diabetes: the PRISMA randomized trial","volume":"36","author":"Bosi","year":"2013","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B142","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.2337\/dc17-1600","article-title":"International consensus on use of continuous glucose monitoring","volume":"40","author":"Danne","year":"2017","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B143","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/S0140-6736(16)31535-5","article-title":"Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial","volume":"388","author":"Bolinder","year":"2016","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B144","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s13300-016-0223-6","article-title":"Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial","volume":"8","author":"Haak","year":"2017","journal-title":"Diabetes Ther"},{"key":"2020042304154226900_ehz486-B145","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B146","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B147","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2337\/db14-0930","article-title":"Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT\/EDIC","volume":"64","author":"Lachin","year":"2015","journal-title":"Diabetes"},{"key":"2020042304154226900_ehz486-B148","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"Nathan","year":"1993","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B149","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B150","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.diabet.2018.05.003","article-title":"Haemoglobin A1c and 5-year all-cause mortality in French type 2 diabetic patients aged 70 years and older: the GERODIAB observational cohort","volume":"44","author":"Doucet","year":"2018","journal-title":"Diabetes Metab"},{"key":"2020042304154226900_ehz486-B151","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2337\/dc14-1329","article-title":"Predictors of nonsevere and severe hypoglycemia during glucose-lowering treatment with insulin glargine or standard drugs in the ORIGIN trial","volume":"38","year":"2015","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B152","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.2337\/db13-1093","article-title":"Diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions","volume":"62","author":"Nathan","year":"2013","journal-title":". Diabetes"},{"key":"2020042304154226900_ehz486-B153","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1161\/CIRCRESAHA.116.305697","article-title":"Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms","volume":"116","author":"Hall","year":"2015","journal-title":"Circ Res"},{"key":"2020042304154226900_ehz486-B154","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1161\/CIRCULATIONAHA.110.016337","article-title":"Blood pressure targets in subjects with type 2 diabetes mellitus\/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials","volume":"123","author":"Bangalore","year":"2011","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B155","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2014.18574","article-title":"Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis","volume":"313","author":"Emdin","year":"2015","journal-title":"JAMA"},{"key":"2020042304154226900_ehz486-B156","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1136\/jnnp-2014-307856","article-title":"Degree of blood pressure reduction and recurrent stroke: the PROGRESS trial","volume":"85","author":"Arima","year":"2014","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"2020042304154226900_ehz486-B157","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00125-017-4537-3","article-title":"Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach","volume":"61","author":"Mancia","year":"2018","journal-title":"Diabetologia"},{"key":"2020042304154226900_ehz486-B158","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B159","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1056\/NEJMoa1407963","article-title":"Follow-up of blood-pressure lowering and glucose control in type 2 diabetes","volume":"371","author":"Zoungas","year":"2014","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B160","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B161","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1056\/NEJM200101043440101","article-title":"Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet","volume":"344","author":"Sacks","year":"2001","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B162","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jacc.2010.09.073","article-title":"The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals","volume":"57","author":"Kastorini","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B163","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/1741-7015-11-207","article-title":"Effect of the Mediterranean diet on blood pressure in the PREDIMED trial: results from a randomized controlled trial","volume":"11","author":"Toledo","year":"2013","journal-title":"BMC Med"},{"key":"2020042304154226900_ehz486-B164","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1007\/s40279-018-0930-4","article-title":"Exercise prescription in patients with different combinations of cardiovascular disease risk factors: a consensus statement from the EXPERT Working Group","volume":"48","author":"Hansen","year":"2018","journal-title":"Sports Med"},{"key":"2020042304154226900_ehz486-B165","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/nrcardio.2016.162","article-title":"Cardiovascular effects of bariatric surgery","volume":"13","author":"Beamish","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"2020042304154226900_ehz486-B166","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc10-2415","article-title":"Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes","volume":"34","author":"Wing","year":"2011","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B167","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","article-title":"Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Lindholm","year":"2002","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B168","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.2337\/diacare.24.12.2091","article-title":"Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic\/beta-blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project","volume":"24","author":"Niskanen","year":"2001","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B169","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1097\/HJH.0b013e328310e0d9","article-title":"The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes","volume":"26","author":"Ostergren","year":"2008","journal-title":"J\u00a0Hypertens"},{"key":"2020042304154226900_ehz486-B170","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2010.02.046","article-title":"Cardiovascular events during differing hypertension therapies in patients with diabetes","volume":"56","author":"Weber","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B171","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjmed.2008.09.038","article-title":"Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials","volume":"122","author":"Wald","year":"2009","journal-title":"Am J Med"},{"key":"2020042304154226900_ehz486-B172","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1161\/HYPERTENSIONAHA.111.189589","article-title":"Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome","volume":"59","author":"Ayers","year":"2012","journal-title":"Hypertension"},{"key":"2020042304154226900_ehz486-B173","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/ajh.2011.8","article-title":"Angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and diabetes: a meta-analysis of placebo-controlled clinical trials","volume":"24","author":"Tocci","year":"2011","journal-title":"Am J Hypertens"},{"key":"2020042304154226900_ehz486-B174","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa065061","article-title":"Effect of ramipril on the incidence of diabetes","volume":"355","author":"Bosch","year":"2006","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B175","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1001121","article-title":"Effect of valsartan on the incidence of diabetes and cardiovascular events","volume":"362","author":"McMurray","year":"2010","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B176","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B177","first-page":"e00407","article-title":"Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"2020042304154226900_ehz486-B178","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/HJH.0000000000000881","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials","volume":"34","author":"Thomopoulos","year":"2016","journal-title":"J\u00a0Hypertens"},{"key":"2020042304154226900_ehz486-B179","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/HJH.0000000000001276","article-title":"Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials","volume":"35","author":"Thomopoulos","year":"2017","journal-title":"J\u00a0Hypertens"},{"key":"2020042304154226900_ehz486-B180","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1097\/HJH.0000000000000379","article-title":"Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels--overview and meta-analyses of randomized trials","volume":"32","author":"Thomopoulos","year":"2014","journal-title":"J\u00a0Hypertens"},{"key":"2020042304154226900_ehz486-B181","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJMoa0806359","article-title":"Long-term follow-up after tight control of blood pressure in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B182","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1001\/archinternmed.2012.3147","article-title":"Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus: systematic review and meta-analysis","volume":"172","author":"McBrien","year":"2012","journal-title":"Arch Intern Med"},{"key":"2020042304154226900_ehz486-B183","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(15)00805-3","article-title":"Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis","volume":"387","author":"Xie","year":"2016","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B184","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(18)30309-X","article-title":"Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial","volume":"391","author":"McManus","year":"2018","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B185","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.HYP.0000215363.69793.bb","article-title":"Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure","volume":"47","author":"Mancia","year":"2006","journal-title":"Hypertension"},{"key":"2020042304154226900_ehz486-B186","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s11892-017-0942-8","article-title":"Treatment of dyslipidemia in diabetes: recent advances and remaining questions","volume":"17","author":"Chait","year":"2017","journal-title":"Curr Diab Rep"},{"key":"2020042304154226900_ehz486-B187","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B188","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jacc.2008.03.051","article-title":"Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials","volume":"52","author":"Nicholls","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B189","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1586\/erc.11.196","article-title":"Statin use during pregnancy: a systematic review and meta-analysis","volume":"10","author":"Kusters","year":"2012","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2020042304154226900_ehz486-B190","doi-asserted-by":"crossref","first-page":"h1035","DOI":"10.1136\/bmj.h1035","article-title":"Statins and congenital malformations: cohort study","volume":"350","author":"Bateman","year":"2015","journal-title":"BMJ"},{"key":"2020042304154226900_ehz486-B191","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B192","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B193","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.amjcard.2009.08.672","article-title":"Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance","volume":"105","author":"Halbert","year":"2010","journal-title":"Am J Cardiol"},{"key":"2020042304154226900_ehz486-B194","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2013.06.004","article-title":"Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience","volume":"166","author":"Mampuya","year":"2013","journal-title":"Am Heart J"},{"key":"2020042304154226900_ehz486-B195","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann Intern Med"},{"key":"2020042304154226900_ehz486-B196","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"2020042304154226900_ehz486-B197","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1001\/jama.2011.860","article-title":"Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis","volume":"305","author":"Preiss","year":"2011","journal-title":"JAMA"},{"key":"2020042304154226900_ehz486-B198","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B199","doi-asserted-by":"crossref","first-page":"e000438","DOI":"10.1136\/bmjdrc-2017-000438","article-title":"Statin use and risk of developing diabetes: results from the Diabetes Prevention Program","volume":"5","author":"Crandall","year":"2017","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2020042304154226900_ehz486-B200","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B201","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B202","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1111\/dom.13114","article-title":"Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial","volume":"19","author":"Leiter","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2020042304154226900_ehz486-B203","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B204","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2020042304154226900_ehz486-B205","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B206","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","article-title":"Committees OO, Investigators. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial","volume":"7","author":"Ray","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2020042304154226900_ehz486-B207","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B208","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ijcard.2008.11.211","article-title":"Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials","volume":"141","author":"Saha","year":"2010","journal-title":"Int J Cardiol"},{"key":"2020042304154226900_ehz486-B209","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3132\/dvdr.2008.046","article-title":"The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient","volume":"5","author":"Fruchart","year":"2008","journal-title":"Diab Vasc Dis Res"},{"key":"2020042304154226900_ehz486-B210","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B211","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B212","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B213","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1373\/clinchem.2008.111401","article-title":"Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS)","volume":"55","author":"Charlton-Menys","year":"2009","journal-title":"Clin Chem"},{"key":"2020042304154226900_ehz486-B214","doi-asserted-by":"crossref","first-page":"e000759","DOI":"10.1161\/JAHA.113.000759","article-title":"Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials","volume":"3","author":"Thanassoulis","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"key":"2020042304154226900_ehz486-B215","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s00125-003-1116-6","article-title":"Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes","volume":"46","author":"Laing","year":"2003","journal-title":"Diabetologia"},{"key":"2020042304154226900_ehz486-B216","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1056\/NEJM199006213222503","article-title":"Thromboxane biosynthesis and platelet function in type II diabetes mellitus","volume":"322","author":"Davi","year":"1990","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B217","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1160\/THS10-11-0739","article-title":"Inflammation and thrombosis in diabetes","volume":"105","author":"Hess","year":"2011","journal-title":"Thromb Haemost"},{"key":"2020042304154226900_ehz486-B218","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/dme.12828","article-title":"Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes","volume":"33","author":"Bethel","year":"2016","journal-title":"Diabet Med"},{"key":"2020042304154226900_ehz486-B219","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1538-7836.2012.04723.x","article-title":"The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes","volume":"10","author":"Rocca","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"2020042304154226900_ehz486-B220","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1160\/TH11-04-0216","article-title":"Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications","volume":"106","author":"Spectre","year":"2011","journal-title":"Thromb Haemost"},{"key":"2020042304154226900_ehz486-B221","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.numecd.2017.06.016","article-title":"Platelet indices and glucose control in type 1 and type 2 diabetes mellitus: a case-control study","volume":"27","author":"Zaccardi","year":"2017","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2020042304154226900_ehz486-B222","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/dmrr.2625","article-title":"Platelet mean volume, distribution width, and count in type 2 diabetes, impaired fasting glucose, and metabolic syndrome: a meta-analysis","volume":"31","author":"Zaccardi","year":"2015","journal-title":"Diabetes Metab Res Rev"},{"key":"2020042304154226900_ehz486-B223","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1161\/01.ATV.17.4.802","article-title":"Megakaryocyte ploidy and platelet changes in human diabetes and atherosclerosis","volume":"17","author":"Brown","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2020042304154226900_ehz486-B224","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12933-017-0515-9","article-title":"Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk","volume":"16","author":"Kearney","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"2020042304154226900_ehz486-B225","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.jacc.2017.08.037","article-title":"Antiplatelet agents for the treatment and prevention of coronary atherothrombosis","volume":"70","author":"Patrono","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B226","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ahj.2012.06.008","article-title":"Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease","volume":"164","author":"Dillinger","year":"2012","journal-title":"Am Heart J"},{"key":"2020042304154226900_ehz486-B227","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B228","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1161\/CIRCULATIONAHA.116.025760","article-title":"Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial","volume":"135","author":"Saito","year":"2017","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B229","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.295.3.306","article-title":"Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials","volume":"295","author":"Berger","year":"2006","journal-title":"JAMA"},{"key":"2020042304154226900_ehz486-B230","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B231","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B232","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S2468-1253(18)30037-2","article-title":"Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials","volume":"3","author":"Scally","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2020042304154226900_ehz486-B233","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(18)31133-4","article-title":"Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials","volume":"392","author":"Rothwell","year":"2018","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B234","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/eurheartj\/ehy066","article-title":"Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis","volume":"39","author":"Rocca","year":"2018","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B235","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1161\/CIRCULATIONAHA.111.019745","article-title":"Antiplatelet therapy and proton pump inhibition: clinician update","volume":"125","author":"Moukarbel","year":"2012","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B236","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2337\/db15-0936","article-title":"In vivo platelet activation and aspirin responsiveness in type 1 diabetes","volume":"65","author":"Zaccardi","year":"2016","journal-title":". Diabetes"},{"key":"2020042304154226900_ehz486-B237","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cpcardiol.2010.10.001","article-title":"Multimodality imaging in diabetic heart disease","volume":"36","author":"Ng","year":"2011","journal-title":"Curr Probl Cardiol"},{"key":"2020042304154226900_ehz486-B238","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12933-015-0296-y","article-title":"Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology","volume":"14","author":"Gyberg","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"2020042304154226900_ehz486-B239","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B240","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3399\/bjgp09X394851","article-title":"Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study","volume":"59","author":"Janssen","year":"2009","journal-title":"Br J Gen Pract"},{"key":"2020042304154226900_ehz486-B241","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/dc13-1544","article-title":"Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with screen-detected diabetes: a randomized controlled trial: the ADDITION-Europe Study","volume":"37","author":"Sandbaek","year":"2014","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B242","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1111\/j.1464-5491.2012.03759.x","article-title":"Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen-detected diabetes? Findings from the ADDITION-Europe cluster-randomized trial","volume":"29","author":"Simmons","year":"2012","journal-title":"Diabet Med"},{"key":"2020042304154226900_ehz486-B243","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/dme.12410","article-title":"Does early intensive multifactorial therapy reduce modelled cardiovascular risk in individuals with screen-detected diabetes? Results from the ADDITION-Europe cluster randomized trial","volume":"31","author":"Black","year":"2014","journal-title":"Diabet Med"},{"key":"2020042304154226900_ehz486-B244","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.kint.2016.11.023","article-title":"Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits","volume":"91","author":"Oellgaard","year":"2017","journal-title":"Kidney Int"},{"key":"2020042304154226900_ehz486-B245","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1007\/s00125-018-4642-y","article-title":"Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study","volume":"61","author":"Oellgaard","year":"2018","journal-title":"Diabetologia"},{"key":"2020042304154226900_ehz486-B246","first-page":"951","article-title":"Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial","volume":"2017;5","author":"Ueki","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2020042304154226900_ehz486-B247","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/HJR.0b013e3282f335d0","article-title":"Evidence-based medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart","volume":"15","author":"Anselmino","year":"2008","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"2020042304154226900_ehz486-B248","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B249","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1093\/eurheartj\/ehl363","article-title":"Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart","volume":"27","author":"Lenzen","year":"2006","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B250","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ahj.2014.06.023","article-title":"Prevalence of glucose abnormalities among patients presenting with an acute myocardial infarction","volume":"168","author":"Arnold","year":"2014","journal-title":"Am Heart J"},{"key":"2020042304154226900_ehz486-B251","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.ehj.2004.07.027","article-title":"The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart","volume":"25","author":"Bartnik","year":"2004","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B252","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B253","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B254","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Montalescot","year":"2013","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B255","article-title":"ESC Guidelines for the diagnosis and management of chronic coronary syndromes","author":"Knuuti","year":"2019","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B256","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B257","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B258","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B259","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2337\/dc09-1278","article-title":"Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial","volume":"33","author":"Riddle","year":"2010","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B260","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0735-1097(95)00126-K","article-title":"Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year","volume":"26","author":"Malmberg","year":"1995","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B261","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1136\/bmj.314.7093.1512","article-title":"Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group","volume":"314","author":"Malmberg","year":"1997","journal-title":"BMJ"},{"key":"2020042304154226900_ehz486-B262","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S2213-8587(14)70088-9","article-title":"Intensified insulin-based glycaemic control after myocardial infarction: mortality during 20 year follow-up of the randomised Diabetes Mellitus Insulin Glucose Infusion in Acute Myocardial Infarction (DIGAMI 1) trial","volume":"2","author":"Ritsinger","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2020042304154226900_ehz486-B263","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/eurheartj\/ehi199","article-title":"Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity","volume":"26","author":"Malmberg","year":"2005","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B264","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1136\/hrt.2010.194563","article-title":"Comparison of glucose-insulin-potassium and insulin-glucose as adjunctive therapy in acute myocardial infarction: a contemporary meta-analysis of randomised controlled trials","volume":"96","author":"Zhao","year":"2010","journal-title":"Heart"},{"key":"2020042304154226900_ehz486-B265","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jacc.2005.03.052","article-title":"U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction","volume":"46","author":"Pinto","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B266","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/eurheartj\/ehi230","article-title":"Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events","volume":"26","author":"Svensson","year":"2005","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B267","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1161\/CIRCULATIONAHA.107.697979","article-title":"Glucose-insulin-potassium for acute myocardial infarction: continuing controversy over cardioprotection","volume":"117","author":"Kloner","year":"2008","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B268","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.amjcard.2014.02.010","article-title":"One-year outcomes of out-of-hospital administration of intravenous glucose, insulin, and potassium (GIK) in patients with suspected acute coronary syndromes (from the IMMEDIATE [Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency Care] Trial)","volume":"113","author":"Selker","year":"2014","journal-title":"Am J Cardiol"},{"key":"2020042304154226900_ehz486-B269","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/ejcts\/ezx314","article-title":"2017 EACTS Guidelines on perioperative medication in adult cardiac surgery","volume":"53","author":"Sousa-Uva","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"key":"2020042304154226900_ehz486-B270","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jtcvs.2010.10.005","article-title":"Superiority of moderate control of hyperglycemia to tight control in patients undergoing coronary artery bypass grafting","volume":"141","author":"Bhamidipati","year":"2011","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"2020042304154226900_ehz486-B271","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1161\/CIRCULATIONAHA.109.913111","article-title":"The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction","volume":"120","author":"Chaitman","year":"2009","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B272","doi-asserted-by":"crossref","first-page":"740","DOI":"10.7326\/M15-2650","article-title":"Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis","volume":"164","author":"Maruthur","year":"2016","journal-title":"Ann Intern Med"},{"key":"2020042304154226900_ehz486-B273","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.diabet.2013.02.006","article-title":"Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes","volume":"39","author":"Scheen","year":"2013","journal-title":"Diabetes Metab"},{"key":"2020042304154226900_ehz486-B274","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/dom.12821","article-title":"Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: a Bayesian meta-analysis of survival data","volume":"19","author":"Bain","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2020042304154226900_ehz486-B275","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/dme.12232","article-title":"Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis","volume":"30","author":"Phung","year":"2013","journal-title":"Diabet Med"},{"key":"2020042304154226900_ehz486-B276","doi-asserted-by":"crossref","first-page":"e1002091","DOI":"10.1371\/journal.pmed.1002091","article-title":"Correction: the association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials","volume":"13","author":"Rados","year":"2016","journal-title":"PLoS Med"},{"key":"2020042304154226900_ehz486-B277","author":"Rosenstock"},{"key":"2020042304154226900_ehz486-B278","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1056\/NEJMoa1001122","article-title":"Effect of nateglinide on the incidence of diabetes and cardiovascular events","volume":"362","author":"Holman","year":"2010","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B279","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B280","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jacc.2006.12.048","article-title":"The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study","volume":"49","author":"Erdmann","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B281","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/01.STR.0000257974.06317.49","article-title":"Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)","volume":"38","author":"Wilcox","year":"2007","journal-title":"Stroke"},{"key":"2020042304154226900_ehz486-B282","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B283","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.2337\/dc07-0717","article-title":"Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08)","volume":"30","author":"Erdmann","year":"2007","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B284","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S2213-8587(17)30317-0","article-title":"Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial","volume":"5","author":"Vaccaro","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2020042304154226900_ehz486-B285","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B286","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/cpt.705","article-title":"Effect of US Food and Drug Administration's cardiovascular safety guidance on diabetes drug development","volume":"102","author":"Hwang","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2020042304154226900_ehz486-B287","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/dci17-0057","article-title":"Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care Editors' Expert Forum","volume":"41","author":"Cefalu","year":"2018","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B288","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11892-017-0898-8","article-title":"Cardiovascular outcome trial update in diabetes: new evidence, remaining questions","volume":"17","author":"Herbst","year":"2017","journal-title":"Curr Diab Rep"},{"key":"2020042304154226900_ehz486-B289","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B290","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1615692","article-title":"Efficacy and safety of degludec versus glargine in type 2 diabetes","volume":"377","author":"Marso","year":"2017","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B291","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B292","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B293","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B294","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"2020042304154226900_ehz486-B295","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1161\/CIRCULATIONAHA.118.038352","article-title":"Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA","volume":"139","author":"McGuire","year":"2019","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B296","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B297","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B298","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B299","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B300","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","author":"Husain","year":"2019","journal-title":"N Engl J Med;"},{"key":"2020042304154226900_ehz486-B301","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B302","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B303","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B304","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B305","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1475-2840-13-102","article-title":"Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME)","volume":"13","author":"Zinman","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"2020042304154226900_ehz486-B306","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B307","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B308","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/dom.12829","article-title":"Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial","volume":"19","author":"Neal","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2020042304154226900_ehz486-B309","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B310","first-page":"80","article-title":"Fracture Risk After Initiation of Use of Canagliflozin","volume-title":"Ann Intern Med","author":"Fralick","year":"2019"},{"key":"2020042304154226900_ehz486-B311","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B312","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B313","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B314","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1093\/eurheartj\/ehw110","article-title":"Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus","volume":"37","author":"Marx","year":"2016","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B315","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00125-016-3956-x","article-title":"SGLT2 inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?","volume":"59","author":"Sattar","year":"2016","journal-title":"Diabetologia"},{"key":"2020042304154226900_ehz486-B316","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"2020042304154226900_ehz486-B317","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamacardio.2017.1891","article-title":"The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure","volume":"2","author":"Verma","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2020042304154226900_ehz486-B318","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.13492","article-title":"Cardiovascular protection in type 2 diabetes: insights from recent outcome trials","volume":"21","author":"Bailey","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2020042304154226900_ehz486-B319","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B320","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jama.2012.12559","article-title":"Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease","volume":"308","author":"Bangalore","year":"2012","journal-title":"JAMA"},{"key":"2020042304154226900_ehz486-B321","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/HYPERTENSIONAHA.117.09259","article-title":"Risk of cardiovascular events in patients with diabetes mellitus on beta-blockers","volume":"70","author":"Tsujimoto","year":"2017","journal-title":"Hypertension"},{"key":"2020042304154226900_ehz486-B322","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.mayocp.2017.11.019","article-title":"Risk of all-cause mortality in diabetic patients taking beta-blockers","volume":"93","author":"Tsujimoto","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"2020042304154226900_ehz486-B323","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B324","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"key":"2020042304154226900_ehz486-B325","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/1074248416644987","article-title":"Effects of carvedilol compared to nebivolol on insulin resistance and lipid profile in patients with essential hypertension","volume":"22","author":"Ozyildiz","year":"2016","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"2020042304154226900_ehz486-B326","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/01.CIR.97.22.2202","article-title":"Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials","volume":"97","year":"1998","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B327","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B328","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.jacc.2013.02.011","article-title":"Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina)","volume":"61","author":"Kosiborod","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B329","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.amjcard.2017.11.021","article-title":"Antihyperglycemic and metabolic effects of ranolazine in patients with diabetes mellitus","volume":"121","author":"Gilbert","year":"2018","journal-title":"Am J Cardiol"},{"key":"2020042304154226900_ehz486-B330","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1016\/S0002-8703(03)00415-0","article-title":"Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy","volume":"146","author":"Fragasso","year":"2003","journal-title":"Am Heart J"},{"key":"2020042304154226900_ehz486-B331","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.ajem.2017.05.024","article-title":"The effect of trimetazidine treatment in patients with type 2 diabetes undergoing percutaneous coronary intervention for AMI","volume":"35","author":"Li","year":"2017","journal-title":"Am J Emerg Med"},{"key":"2020042304154226900_ehz486-B332","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1365-2125.1994.tb04276.x","article-title":"Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group","volume":"37","author":"Detry","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"2020042304154226900_ehz486-B333","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2217\/cer-2017-0011","article-title":"Effectiveness and safety of anti-ischemic trimetazidine in patients with stable angina pectoris and Type 2 diabetes","volume":"6","author":"Meiszterics","year":"2017","journal-title":"J\u00a0Comp Eff Res"},{"key":"2020042304154226900_ehz486-B334"},{"key":"2020042304154226900_ehz486-B335","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/ejhf.347","article-title":"Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial","volume":"17","author":"Komajda","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2020042304154226900_ehz486-B336","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B337","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.amjcard.2009.01.342","article-title":"Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial)","volume":"103","author":"Dasgupta","year":"2009","journal-title":"Am J Cardiol"},{"key":"2020042304154226900_ehz486-B338","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","article-title":"Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38","volume":"118","author":"Wiviott","year":"2008","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B339","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/eurheartj\/ehq325","article-title":"Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"31","author":"James","year":"2010","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B340","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1016\/j.jacc.2016.03.529","article-title":"Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54","volume":"67","author":"Bhatt","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B341","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B342","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B343","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0140-6736(17)32458-3","article-title":"Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Connolly","year":"2018","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B344","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B345","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B346","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B347","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group","volume":"355","author":"Flather","year":"2000","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B348","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/eurheartj\/ehr035","article-title":"Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients","volume":"32","author":"Mills","year":"2011","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B349","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients","volume":"308","year":"1994","journal-title":"BMJ"},{"key":"2020042304154226900_ehz486-B350","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B351","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B352","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"2020042304154226900_ehz486-B353","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B354","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1161\/CIRCULATIONAHA.113.004420","article-title":"PLATO study group. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial","volume":"129","author":"Wallentin","year":"2014","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B355","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B356","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B357","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0735-1097(01)01183-4","article-title":"New diagnostic criteria for diabetes and coronary artery disease: insights from an angiographic study","volume":"37","author":"Ledru","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B358","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa0805796","article-title":"A randomized trial of therapies for type 2 diabetes and coronary artery disease","volume":"360","author":"Frye","year":"2009","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B359","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1161\/CIRCINTERVENTIONS.111.963512","article-title":"Impact of completeness of revascularization on long-term cardiovascular outcomes in patients with type 2 diabetes mellitus: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D)","volume":"5","author":"Schwartz","year":"2012","journal-title":"Circ Cardiovasc Interv"},{"key":"2020042304154226900_ehz486-B360","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa1602001","article-title":"Coronary-artery bypass surgery in patients with ischemic cardiomyopathy","volume":"374","author":"Velazquez","year":"2016","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B361","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jacc.2012.02.059","article-title":"An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials","volume":"60","author":"O'Donoghue","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B362","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(17)31490-3","article-title":"Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials","volume":"390","author":"Jobs","year":"2017","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B363","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jacc.2012.11.044","article-title":"Percutaneous coronary intervention versus coronary bypass surgery in United States veterans with diabetes","volume":"61","author":"Kamalesh","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B364","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jacc.2009.10.014","article-title":"Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial","volume":"55","author":"Kapur","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B365","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1211585","article-title":"Strategies for multivessel revascularization in patients with diabetes","volume":"367","author":"Farkouh","year":"2012","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B366","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jacc.2014.06.1182","article-title":"Long-term outcome of PCI versus CABG in insulin and non-insulin-treated diabetic patients: results from the FREEDOM trial","volume":"64","author":"Dangas","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B367","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/ejcts\/ezt017","article-title":"Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial","volume":"43","author":"Kappetein","year":"2013","journal-title":"Eur J Cardiothorac Surg"},{"key":"2020042304154226900_ehz486-B368","doi-asserted-by":"crossref","first-page":"e000354","DOI":"10.1161\/JAHA.113.000354","article-title":"Effectiveness of percutaneous coronary intervention with drug-eluting stents compared with bypass surgery in diabetics with multivessel coronary disease: comprehensive systematic review and meta-analysis of randomized clinical data","volume":"2","author":"Hakeem","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"key":"2020042304154226900_ehz486-B369","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(18)30423-9","article-title":"Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data","volume":"391","author":"Head","year":"2018","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B370","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijcard.2016.12.116","article-title":"Efficacy and safety of everolimus and zotarolimus-eluting stents versus first-generation drug-eluting stents in patients with diabetes: a meta-analysis of randomized trials","volume":"230","author":"Bavishi","year":"2017","journal-title":"Int J Cardiol"},{"key":"2020042304154226900_ehz486-B371","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa1415447","article-title":"Trial of everolimus-eluting stents or bypass surgery for coronary disease","volume":"372","author":"Park","year":"2015","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B372","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1056\/NEJMoa1610227","article-title":"Everolimus-eluting stents or bypass surgery for left main coronary artery disease","volume":"375","author":"Stone","year":"2016","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B373","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1016\/j.jacc.2017.10.029","article-title":"Surgical versus percutaneous coronary revascularization in patients with diabetes and acute coronary syndromes","volume":"70","author":"Ramanathan","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B374","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jacc.2017.12.024","article-title":"Coronary artery bypass surgery improves outcomes in patients with diabetes and left ventricular dysfunction","volume":"71","author":"Nagendran","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B375","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Seferovic","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2020042304154226900_ehz486-B376","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jacc.2017.05.061","article-title":"Influence of diabetes on long-term coronary artery bypass graft patency","volume":"70","author":"Raza","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B377","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1161\/CIRCULATIONAHA.113.004255","article-title":"Effect of bilateral internal mammary artery grafts on long-term survival: a meta-analysis approach","volume":"130","author":"Yi","year":"2014","journal-title":"Circulation"},{"issue":"1","key":"2020042304154226900_ehz486-B378","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.008010","article-title":"Unmeasured Confounders in Observational Studies Comparing Bilateral Versus Single Internal Thoracic Artery for Coronary Artery Bypass Grafting: A Meta-Analysis","volume":"7","author":"Gaudino","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2020042304154226900_ehz486-B379","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMoa1610021","article-title":"Randomized trial of bilateral versus single internal-thoracic-artery grafts","volume":"375","author":"Taggart","year":"2016","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B380","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa1808783","article-title":"Bilateral versus single internal-thoracic-artery grafts at 10 years","volume":"380","author":"Taggart","year":"2019","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B381","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa1716026","article-title":"Radial-artery or saphenous-vein grafts in coronary-artery bypass surgery","volume":"378","author":"Gaudino","year":"2018","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B382","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/bmj.39106.476215.BE","article-title":"Meta-analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery","volume":"334","author":"Aziz","year":"2007","journal-title":"BMJ"},{"key":"2020042304154226900_ehz486-B383","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jcin.2012.09.008","article-title":"Comparison of bare-metal stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 10-year follow-up of a randomized trial","volume":"6","author":"Blazek","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"key":"2020042304154226900_ehz486-B384","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jcin.2014.08.006","article-title":"Comparison of sirolimus-eluting stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery: 7-year follow-up of a randomized trial","volume":"8","author":"Blazek","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"2020042304154226900_ehz486-B385","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.jacc.2014.09.074","article-title":"Coronary artery bypass graft surgery versus drug-eluting stents for patients with isolated proximal left anterior descending disease","volume":"64","author":"Hannan","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B386","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.amjmed.2008.07.027","article-title":"The impact of revascularization on mortality in patients with nonacute coronary artery disease","volume":"122","author":"Jeremias","year":"2009","journal-title":"Am J Med"},{"key":"2020042304154226900_ehz486-B387","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jcin.2008.07.001","article-title":"Isolated disease of the proximal left anterior descending artery comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery","volume":"1","author":"Kapoor","year":"2008","journal-title":"JACC Cardiovasc Interv"},{"key":"2020042304154226900_ehz486-B388","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2009.03.032","article-title":"Randomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis","volume":"53","author":"Thiele","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B389","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(94)91963-1","article-title":"Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration","volume":"344","author":"Yusuf","year":"1994","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B390","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1067\/mhj.2001.116072","article-title":"Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: a report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators","volume":"142","author":"Dzavik","year":"2001","journal-title":"Am Heart J"},{"key":"2020042304154226900_ehz486-B391","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa071804","article-title":"Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease","volume":"358","author":"Hannan","year":"2008","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B392","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1056\/NEJMoa1412168","article-title":"Everolimus-eluting stents or bypass surgery for multivessel coronary disease","volume":"372","author":"Bangalore","year":"2015","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B393","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1161\/CIRCINTERVENTIONS.115.002626","article-title":"Everolimus eluting stents versus coronary artery bypass graft surgery for patients with diabetes mellitus and multivessel disease","volume":"8","author":"Bangalore","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"2020042304154226900_ehz486-B394","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1093\/eurheartj\/ehu213","article-title":"Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial","volume":"35","author":"Head","year":"2014","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B395","doi-asserted-by":"crossref","first-page":"e010055","DOI":"10.1136\/bmjopen-2015-010055","article-title":"Has the difference in mortality between percutaneous coronary intervention and coronary artery bypass grafting in people with heart disease and diabetes changed over the years? A systematic review and meta-regression","volume":"5","author":"Herbison","year":"2015","journal-title":"BMJ Open"},{"key":"2020042304154226900_ehz486-B396","doi-asserted-by":"crossref","first-page":"e003255","DOI":"10.1161\/CIRCINTERVENTIONS.115.003255","article-title":"Impact of diabetic status on outcomes after revascularization with drug-eluting stents in relation to coronary artery disease complexity: patient-level pooled analysis of 6081 patients","volume":"9","author":"Koskinas","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"2020042304154226900_ehz486-B397","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(13)60141-5","article-title":"Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial","volume":"381","author":"Mohr","year":"2013","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B398","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJMoa0804626","article-title":"Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease","volume":"360","author":"Serruys","year":"2009","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B399","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.jacc.2015.03.033","article-title":"Randomized trial of stents versus bypass surgery for left main coronary artery disease: 5-year outcomes of","volume":"65","author":"Ahn","year":"2015","journal-title":"the PRECOMBAT study. J Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B400","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1161\/CIRCULATIONAHA.112.000646","article-title":"Bayesian methods affirm the use of percutaneous coronary intervention to improve survival in patients with unprotected left main coronary artery disease","volume":"127","author":"Bittl","year":"2013","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B401","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.jacc.2011.07.005","article-title":"Percutaneous coronary intervention versus coronary artery bypass graft surgery in left main coronary artery disease: a meta-analysis of randomized clinical data","volume":"58","author":"Capodanno","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B402","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jacc.2016.06.024","article-title":"Outcomes after percutaneous coronary intervention or bypass surgery in patients with unprotected left main disease","volume":"68","author":"Cavalcante","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B403","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/jamacardio.2017.2895","article-title":"Percutaneous coronary intervention vs coronary artery bypass grafting in patients with left main coronary artery stenosis: a systematic review and meta-analysis","volume":"2","author":"Giacoppo","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2020042304154226900_ehz486-B404","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1161\/CIRCULATIONAHA.113.006689","article-title":"Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial","volume":"129","author":"Morice","year":"2014","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B405","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0002-9149(99)00392-6","article-title":"Comparison of incidences of congestive heart failure in older African-Americans, Hispanics, and whites","volume":"84","author":"Aronow","year":"1999","journal-title":"Am J Cardiol"},{"key":"2020042304154226900_ehz486-B406","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0002-9343(99)00126-6","article-title":"Risk factors for heart failure in the elderly: a prospective community-based study","volume":"106","author":"Chen","year":"1999","journal-title":"Am J Med"},{"key":"2020042304154226900_ehz486-B407","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/S0735-1097(00)00582-9","article-title":"Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study","volume":"35","author":"Gottdiener","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B408","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2011.07.030","article-title":"Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis","volume":"162","author":"Castagno","year":"2011","journal-title":"Am Heart J"},{"key":"2020042304154226900_ehz486-B409","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1007\/s00125-012-2579-0","article-title":"High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes","volume":"55","author":"Boonman-de Winter","year":"2012","journal-title":"Diabetologia"},{"key":"2020042304154226900_ehz486-B410","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.2337\/diacare.27.8.1879","article-title":"The incidence of congestive heart failure in type 2 diabetes: an update","volume":"27","author":"Nichols","year":"2004","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B411","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.2337\/diacare.24.9.1614","article-title":"Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors","volume":"24","author":"Nichols","year":"2001","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B412","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.2337\/db10-0165","article-title":"The association of hemoglobin a1c with incident heart failure among people without diabetes: the atherosclerosis risk in communities study","volume":"59","author":"Matsushita","year":"2010","journal-title":"Diabetes"},{"key":"2020042304154226900_ehz486-B413","first-page":"213","article-title":"Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group","volume":"23","author":"Amato","year":"1997","journal-title":"Diabetes Metab"},{"key":"2020042304154226900_ehz486-B414","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/ehjci\/jes165","article-title":"Abnormal glucose metabolism is associated with reduced left ventricular contractile reserve and exercise intolerance in patients with chronic heart failure","volume":"14","author":"Egstrup","year":"2013","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2020042304154226900_ehz486-B415","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ijcard.2004.10.024","article-title":"Prevalence and characteristics of diabetic patients in a chronic heart failure population","volume":"100","author":"Kistorp","year":"2005","journal-title":"Int J Cardiol"},{"key":"2020042304154226900_ehz486-B416","doi-asserted-by":"crossref","first-page":"612","DOI":"10.2337\/diacare.28.3.612","article-title":"The association between glucose abnormalities and heart failure in the population-based Reykjavik study","volume":"28","author":"Thrainsdottir","year":"2005","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B417","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2020042304154226900_ehz486-B418","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/1479164118794619","article-title":"Type 2 diabetes and heart failure: characteristics and prognosis in preserved, mid-range and reduced ventricular function","volume":"15","author":"Johansson","year":"2018","journal-title":"Diab Vasc Dis Res"},{"key":"2020042304154226900_ehz486-B419","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","year":"1997","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B420","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B421","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B422","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1161\/CIRCULATIONAHA.106.628347","article-title":"Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial","volume":"114","author":"Ahmed","year":"2006","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B423","doi-asserted-by":"crossref","first-page":"e005156","DOI":"10.1161\/JAHA.116.005156","article-title":"Prognostic impact of diabetes and prediabetes on survival outcomes in patients with chronic heart failure: a post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) trial","volume":"6","author":"Dauriz","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"2020042304154226900_ehz486-B424","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1056\/NEJMoa1601895","article-title":"Effect of ularitide on cardiovascular mortality in acute heart failure","volume":"376","author":"Packer","year":"2017","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B425","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(03)14282-1","article-title":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme","volume":"362","author":"Pfeffer","year":"2003","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B426","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2337\/dc16-2016","article-title":"Association between diabetes and 1-year adverse clinical outcomes in a multinational cohort of ambulatory patients with chronic heart failure: results from the ESC-HFA Heart Failure Long-Term Registry","volume":"40","author":"Dauriz","year":"2017","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B427","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ejhf.679","article-title":"In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry","volume":"19","author":"Targher","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2020042304154226900_ehz486-B428","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00125-014-3259-z","article-title":"Association of heart failure severity with risk of diabetes: a Danish nationwide cohort study","volume":"57","author":"Demant","year":"2014","journal-title":"Diabetologia"},{"key":"2020042304154226900_ehz486-B429","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796","article-title":"Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry","volume":"132","author":"Cavender","year":"2015","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B430","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jacc.2016.06.061","article-title":"Prognostic implications of type 2 diabetes mellitus in ischemic and nonischemic heart failure","volume":"68","author":"Johansson","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B431","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10557-017-6754-x","article-title":"Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes","volume":"31","author":"Kristensen","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"2020042304154226900_ehz486-B432","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","article-title":"Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme","volume":"29","author":"MacDonald","year":"2008","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B433","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/CIRCULATIONAHA.116.024593","article-title":"Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I-Preserve trial (Irbesartan in Heart Failure With Preserved Ejection Fraction)","volume":"135","author":"Kristensen","year":"2017","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B434","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B435","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/ejhf.600","article-title":"Reframing the association and significance of co-morbidities in heart failure","volume":"18","author":"Triposkiadis","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2020042304154226900_ehz486-B436","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/2047487318807767","article-title":"Long-term mortality is increased in patients with undetected prediabetes and type-2 diabetes hospitalized for worsening heart failure and reduced ejection fraction","volume":"26","author":"Pavlovic","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2020042304154226900_ehz486-B437","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ejhf.566","article-title":"European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions","volume":"18","author":"Crespo-Leiro","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2020042304154226900_ehz486-B438","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","article-title":"Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes","volume":"36","author":"Seferovic","year":"2015","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B439","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/bmj.321.7258.412","article-title":"Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study","volume":"321","author":"Adler","year":"2000","journal-title":"BMJ"},{"key":"2020042304154226900_ehz486-B440","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2337\/diacare.27.3.699","article-title":"Heart failure prevalence, incidence, and mortality in the elderly with diabetes","volume":"27","author":"Bertoni","year":"2004","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B441","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.amjcard.2005.07.061","article-title":"Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies","volume":"96","author":"Carr","year":"2005","journal-title":"Am J Cardiol"},{"key":"2020042304154226900_ehz486-B442","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1093\/eurheartj\/ehy596","article-title":"Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology","volume":"39","author":"Maack","year":"2018","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B443","doi-asserted-by":"crossref","first-page":"743503","DOI":"10.1155\/2015\/743503","article-title":"Evidence for a specific diabetic cardiomyopathy: an observational retrospective echocardiographic study in 656 asymptomatic type 2 diabetic patients","volume":"2015","author":"Pham","year":"2015","journal-title":"Int J Endocrinol"},{"key":"2020042304154226900_ehz486-B444","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s001250050924","article-title":"The effect of intensive diabetes therapy on measures of autonomic nervous system function in the Diabetes Control and Complications Trial (DCCT","volume":"41","year":"1998","journal-title":"Diabetologia"},{"key":"2020042304154226900_ehz486-B445","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.2337\/diacare.22.7.1186","article-title":"Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes","volume":"22","author":"Berg","year":"1999","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B446","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.ejheart.2007.09.009","article-title":"Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications","volume":"9","author":"Hartog","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"2020042304154226900_ehz486-B447","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.jacc.2008.07.062","article-title":"Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus","volume":"52","author":"Rijzewijk","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B448","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1161\/CIRCULATIONAHA.110.014506","article-title":"Altered mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus","volume":"124","author":"Shenouda","year":"2011","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B449","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.amjcard.2003.12.026","article-title":"Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus","volume":"93","author":"Boyer","year":"2004","journal-title":"Am J Cardiol"},{"key":"2020042304154226900_ehz486-B450","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1475-2840-9-63","article-title":"Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic function: a cross-sectional study","volume":"9","author":"Dinh","year":"2010","journal-title":"Cardiovasc Diabetol"},{"key":"2020042304154226900_ehz486-B451","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jama.294.3.334","article-title":"Insulin resistance and risk of congestive heart failure","volume":"294","author":"Ingelsson","year":"2005","journal-title":"JAMA"},{"key":"2020042304154226900_ehz486-B452","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0735-1097(01)01230-X","article-title":"The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study","volume":"37","author":"Liu","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B453","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s00125-010-1718-8","article-title":"Association of glucose metabolism with diastolic function along the diabetic continuum","volume":"53","author":"Stahrenberg","year":"2010","journal-title":"Diabetologia"},{"key":"2020042304154226900_ehz486-B454","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.amjcard.2009.09.041","article-title":"Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus","volume":"105","author":"Aguilar","year":"2010","journal-title":"Am J Cardiol"},{"key":"2020042304154226900_ehz486-B455","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.2013.1954","article-title":"Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial","volume":"309","author":"Gheorghiade","year":"2013","journal-title":"JAMA"},{"key":"2020042304154226900_ehz486-B456","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ejhf.1072","article-title":"Renin inhibition in heart failure and diabetes: the real story","volume":"20","author":"Rosano","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2020042304154226900_ehz486-B457","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B458","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0735-1097(99)00146-1","article-title":"Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction","volume":"34","author":"Gustafsson","year":"1999","journal-title":"Trace Study Group. J Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B459","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B460","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/S0735-1097(02)02304-5","article-title":"Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors","volume":"40","author":"Maggioni","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B461","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/eurheartj\/15.suppl_B.2","article-title":"Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study","volume":"15","author":"Moye","year":"1994","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B462","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/S0735-1097(03)00262-6","article-title":"Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials","volume":"41","author":"Shekelle","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B463","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1053\/euhj.2000.2311","article-title":"Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial","volume":"21","author":"Ryden","year":"2000","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B464","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jacc.2005.05.051","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"46","author":"Abuissa","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B465","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B466","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B467","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B468","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2016_76","article-title":"Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside","volume":"243","author":"Kolkhof","year":"2017","journal-title":"Handb Exp Pharmacol"},{"key":"2020042304154226900_ehz486-B469","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1161\/CIRCHEARTFAILURE.114.001104","article-title":"Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist","volume":"7","author":"Vardeny","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2020042304154226900_ehz486-B470","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.mcna.2004.06.001","article-title":"The global epidemiology of heart failure","volume":"88","author":"Young","year":"2004","journal-title":"Med Clin North Am"},{"issue":"1","key":"2020042304154226900_ehz486-B471","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002560","article-title":"Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial","volume":"9","author":"Kristensen","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2020042304154226900_ehz486-B472","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","article-title":"Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial","volume":"5","author":"Seferovic","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2020042304154226900_ehz486-B473","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1054\/jcaf.2003.31","article-title":"Survival and hospitalization in heart failure patients with or without diabetes treated with beta-blockers","volume":"9","author":"Bobbio","year":"2003","journal-title":"J\u00a0Card Fail"},{"key":"2020042304154226900_ehz486-B474","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ahj.2004.05.056","article-title":"Efficacy, safety and tolerability of metoprolol CR\/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF","volume":"149","author":"Deedwania","year":"2005","journal-title":"Am Heart J"},{"key":"2020042304154226900_ehz486-B475","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S1388-9842(01)00174-X","article-title":"Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure","volume":"3","author":"Erdmann","year":"2001","journal-title":"Eur J Heart Fail"},{"key":"2020042304154226900_ehz486-B476","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B477","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ijcard.2016.02.074","article-title":"Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: an analysis of the Digitalis Investigation Group (DIG) trial","volume":"209","author":"Abdul-Rahim","year":"2016","journal-title":"Int J Cardiol"},{"key":"2020042304154226900_ehz486-B478","first-page":"CD003838","article-title":"Diuretics for heart failure","volume":"2","author":"Faris","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2020042304154226900_ehz486-B479","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa032423","article-title":"Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure","volume":"350","author":"Bristow","year":"2004","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B480","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.cardfail.2007.06.723","article-title":"Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure","volume":"13","author":"Ghali","year":"2007","journal-title":"J\u00a0Card Fail"},{"key":"2020042304154226900_ehz486-B481","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMoa1608029","article-title":"Defibrillator implantation in patients with nonischemic systolic heart failure","volume":"375","author":"Kober","year":"2016","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B482","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/ejhf.288","article-title":"Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trial","volume":"17","author":"MacDonald","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2020042304154226900_ehz486-B483","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.athoracsur.2011.09.037","article-title":"What predicts long-term survival after heart transplantation? An analysis of 9,400 ten-year survivors","volume":"93","author":"Kilic","year":"2012","journal-title":"Ann Thorac Surg"},{"key":"2020042304154226900_ehz486-B484","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2337\/diacare.28.10.2345","article-title":"Improved clinical outcomes associated with metformin in patients with diabetes and heart failure","volume":"28","author":"Eurich","year":"2005","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B485","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/01.CIR.0000154542.13412.B1","article-title":"Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study","volume":"111","author":"Masoudi","year":"2005","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B486","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1161\/CIRCHEARTFAILURE.112.000162","article-title":"Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients","volume":"6","author":"Eurich","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2020042304154226900_ehz486-B487","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00592-008-0090-3","article-title":"The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis","volume":"46","author":"Pantalone","year":"2009","journal-title":"Acta Diabetol"},{"key":"2020042304154226900_ehz486-B488","doi-asserted-by":"crossref","first-page":"b4731","DOI":"10.1136\/bmj.b4731","article-title":"Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database","volume":"339","author":"Tzoulaki","year":"2009","journal-title":"BMJ"},{"key":"2020042304154226900_ehz486-B489","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.diabres.2016.04.055","article-title":"Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality","volume":"117","author":"Eriksson","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"key":"2020042304154226900_ehz486-B490","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.2337\/diacare.25.10.1737","article-title":"A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes","volume":"25","author":"Viberti","year":"2002","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B491","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(06)69420-8","article-title":"Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial","volume":"368","author":"Gerstein","year":"2006","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B492","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2165\/11587580-000000000-00000","article-title":"Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials","volume":"11","author":"Hernandez","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"key":"2020042304154226900_ehz486-B493","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B494","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.2337\/dc18-S009","article-title":"9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B495","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jchf.2017.08.004","article-title":"Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial","volume":"6","author":"McMurray","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2020042304154226900_ehz486-B496","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study)","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B497","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0735-1097(03)00856-8","article-title":"The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial","volume":"42","author":"Domanski","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"2020042304154226900_ehz486-B498","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2020042304154226900_ehz486-B499","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"2020042304154226900_ehz486-B500","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ahj.2004.07.005","article-title":"Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure","volume":"149","author":"Smooke","year":"2005","journal-title":"Am Heart J"},{"key":"2020042304154226900_ehz486-B501","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/2047487315599892","article-title":"Risk of atrial fibrillation in diabetes mellitus: a nationwide cohort study","volume":"23","author":"Pallisgaard","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"2020042304154226900_ehz486-B502","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/eurheartj\/ehp055","article-title":"Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study","volume":"30","author":"Du","year":"2009","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B503","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B504","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/europace\/euu194","article-title":"EHRA\/HRS\/APHRS expert consensus on ventricular arrhythmias","volume":"16","author":"Pedersen","year":"2014","journal-title":"Europace"},{"key":"2020042304154226900_ehz486-B505","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1093\/eurheartj\/eht150","article-title":"2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA)","volume":"34","author":"Brignole","year":"2013","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B506","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","article-title":"2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)","volume":"36","author":"Priori","year":"2015","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B507","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1093\/eurheartj\/ehi376","article-title":"Diabetes, glucose level, and risk of sudden cardiac death","volume":"26","author":"Jouven","year":"2005","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B508","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1161\/01.CIR.91.10.2591","article-title":"Sudden death, impaired glucose tolerance, and diabetes in Japanese American men","volume":"91","author":"Curb","year":"1995","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B509","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00592-009-0157-9","article-title":"Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities study","volume":"47","author":"Kucharska-Newton","year":"2010","journal-title":"Acta Diabetol"},{"key":"2020042304154226900_ehz486-B510","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1053\/hj.1998.v136.90226","article-title":"Sudden coronary death in women","volume":"136","author":"Kannel","year":"1998","journal-title":"Am Heart J"},{"key":"2020042304154226900_ehz486-B511","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.hrthm.2010.07.031","article-title":"Sudden cardiac death after myocardial infarction in patients with type 2 diabetes","volume":"7","author":"Junttila","year":"2010","journal-title":"Heart Rhythm"},{"key":"2020042304154226900_ehz486-B512","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.2337\/db13-0468","article-title":"Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk","volume":"63","author":"Chow","year":"2014","journal-title":". Diabetes"},{"key":"2020042304154226900_ehz486-B513","first-page":"840","article-title":"Independent risk factors for atrial fibrillation in a population-based cohort","volume":"271","author":"Benjamin","year":"1994","journal-title":"The Framingham Heart Study. JAMA"},{"key":"2020042304154226900_ehz486-B514","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"2020042304154226900_ehz486-B515","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0002-9343(99)80348-9","article-title":"The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study","volume":"98","author":"Krahn","year":"1995","journal-title":"Am J Med"},{"key":"2020042304154226900_ehz486-B516","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2337\/dc09-0939","article-title":"Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation","volume":"32","author":"Nichols","year":"2009","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B517","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1161\/01.CIR.96.7.2455","article-title":"Incidence of and risk factors for atrial fibrillation in older adults","volume":"96","author":"Psaty","year":"1997","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B518","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1111\/dom.13348","article-title":"Association of hypoglycaemia and risk of cardiac arrhythmia in patients with diabetes mellitus: a systematic review and meta-analysis","volume":"20","author":"Fitzpatrick","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2020042304154226900_ehz486-B519","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jdiacomp.2015.08.011","article-title":"Abdominal aortic aneurysms and diabetes mellitus","volume":"29","author":"Pafili","year":"2015","journal-title":"J\u00a0Diabetes Complications"},{"key":"2020042304154226900_ehz486-B520","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejvs.2013.12.007","article-title":"Diabetes and abdominal aortic aneurysms","volume":"47","author":"De Rango","year":"2014","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2020042304154226900_ehz486-B521","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1093\/eurheartj\/ehu281","article-title":"2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC)","volume":"35","author":"Erbel","year":"2014","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B522","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS)","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"key":"2020042304154226900_ehz486-B523","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/CIRCRESAHA.116.303849","article-title":"Epidemiology of peripheral artery disease","volume":"116","author":"Criqui","year":"2015","journal-title":"Circ Res"},{"key":"2020042304154226900_ehz486-B524","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jdiacomp.2014.02.008","article-title":"Prevalence and associations of diabetic retinopathy in a large cohort of prediabetic subjects: the Gutenberg Health Study","volume":"28","author":"Lamparter","year":"2014","journal-title":"J\u00a0Diabetes Complications"},{"key":"2020042304154226900_ehz486-B525","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2337\/dc09-0831","article-title":"Long-term outcomes of diabetic patients with critical limb ischemia followed in a tertiary referral diabetic foot clinic","volume":"33","author":"Uccioli","year":"2010","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B526","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1161\/CIRCULATIONAHA.105.548099","article-title":"Exertional leg pain in patients with and without peripheral arterial disease","volume":"112","author":"Wang","year":"2005","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B527","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/1358863X17751259","article-title":"Diagnostic accuracy of the postexercise ankle-brachial index for detecting peripheral artery disease in suspected claudicants with and without diabetes","volume":"23","author":"Tehan","year":"2018","journal-title":"Vasc Med"},{"key":"2020042304154226900_ehz486-B528","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.300.2.197","article-title":"Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis","volume":"300","author":"Fowkes","year":"2008","journal-title":"JAMA"},{"key":"2020042304154226900_ehz486-B529","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1161\/CIR.0b013e318276fbcb","article-title":"Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association","volume":"126","author":"Aboyans","year":"2012","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B530","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.jvs.2008.06.005","article-title":"The association between elevated ankle systolic pressures and peripheral occlusive arterial disease in diabetic and nondiabetic subjects","volume":"48","author":"Aboyans","year":"2008","journal-title":"J\u00a0Vasc Surg"},{"key":"2020042304154226900_ehz486-B531","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B532","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"key":"2020042304154226900_ehz486-B533","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ahj.2017.12.006","article-title":"ASCEND: A Study of Cardiovascular Events iN Diabetes: characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes","volume":"198","author":"Bowman","year":"2018","journal-title":"Am Heart J"},{"key":"2020042304154226900_ehz486-B534","first-page":"363","article-title":"Intensive walking exercise for lower extremity peripheral arterial disease: a systematic review and meta-analysis","volume":"8","author":"Lyu","year":"2016","journal-title":"J\u00a0Diabetes"},{"key":"2020042304154226900_ehz486-B535","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/1358863X14538330","article-title":"Association of elevated fasting glucose with lower patency and increased major adverse limb events among patients with diabetes undergoing infrapopliteal balloon angioplasty","volume":"19","author":"Singh","year":"2014","journal-title":"Vasc Med"},{"key":"2020042304154226900_ehz486-B536","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.2337\/dc10-0939","article-title":"The influence of glycemic control on the prognosis of Japanese patients undergoing percutaneous transluminal angioplasty for critical limb ischemia","volume":"33","author":"Takahara","year":"2010","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B537","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/dmrr.2705","article-title":"Effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral artery disease: a systematic review","volume":"32","author":"Hinchliffe","year":"2016","journal-title":"Diabetes Metab Res Rev"},{"key":"2020042304154226900_ehz486-B538","doi-asserted-by":"crossref","first-page":"e0180804","DOI":"10.1371\/journal.pone.0180804","article-title":"Long-term efficacy and safety of carotid artery stenting versus endarterectomy: a meta-analysis of randomized controlled trials","volume":"12","author":"Li","year":"2017","journal-title":"PLoS One"},{"issue":"1107","key":"2020042304154226900_ehz486-B539","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jvs.2015.12.041","article-title":"Impact of diabetes on carotid artery revascularization","volume":"63","author":"Hussain","year":"2016","journal-title":"J\u00a0Vasc Surg"},{"key":"2020042304154226900_ehz486-B540","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S1474-4422(12)70159-X","article-title":"Restenosis after carotid artery stenting and endarterectomy: a secondary analysis of CREST, a randomised controlled trial","volume":"11","author":"Lal","year":"2012","journal-title":"Lancet Neurol"},{"key":"2020042304154226900_ehz486-B541","article-title":"Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev","volume":"2","author":"Bedenis","year":"2015","journal-title":"CD000535"},{"key":"2020042304154226900_ehz486-B542","doi-asserted-by":"crossref","first-page":"32S","DOI":"10.1016\/j.jvs.2010.01.075","article-title":"Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: a description of the severity and extent of disease using the Bollinger angiogram scoring method and the TransAtlantic Inter-Society Consensus II classification","volume":"51","author":"Bradbury","year":"2010","journal-title":"J\u00a0Vasc Surg"},{"key":"2020042304154226900_ehz486-B543","first-page":"1","article-title":"KDIGO 2012 Clinical Practice Guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2020042304154226900_ehz486-B544","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2015.12.014","article-title":"US Renal Data System 2015 Annual Data Report: epidemiology of kidney disease in the United States","volume":"67","author":"Saran","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2020042304154226900_ehz486-B545","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s12325-015-0261-x","article-title":"Overview of data concerning the safe use of antihyperglycemic medications in type 2 diabetes mellitus and chronic kidney disease","volume":"32","author":"Roussel","year":"2015","journal-title":"Adv Ther"},{"key":"2020042304154226900_ehz486-B546","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2337\/dc15-2322","article-title":"Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON","volume":"39","author":"Wong","year":"2016","journal-title":"Diabetes Care"},{"key":"2020042304154226900_ehz486-B547","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1517\/17425255.2013.777428","article-title":"Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease","volume":"9","author":"Scheen","year":"2013","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2020042304154226900_ehz486-B548","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B549","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ckj\/sfy090","article-title":"The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study","volume":"11","author":"Herrington","year":"2018","journal-title":"Clin Kidney J"},{"key":"2020042304154226900_ehz486-B550","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000484633","article-title":"The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics","volume":"46","author":"Jardine","year":"2017","journal-title":"Am J Nephrol"},{"key":"2020042304154226900_ehz486-B551","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(09)61457-4","article-title":"10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study","volume":"374","author":"Knowler","year":"2009","journal-title":"Lancet"},{"key":"2020042304154226900_ehz486-B552","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMsa1213829","article-title":"Achievement of goals in U.S. diabetes care, 1999-2010","volume":"368","author":"Ali","year":"2013","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B553","first-page":"CD010523","article-title":"Personalised care planning for adults with chronic or long-term health conditions","volume":"3","author":"Coulter","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2020042304154226900_ehz486-B554","first-page":"CD003267","article-title":"Interventions for providers to promote a patient-centred approach in clinical consultations","volume":"4","author":"Lewin","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"2020042304154226900_ehz486-B555","volume-title":"Crossing the Quality Chasm: A New Health System for the 21st Century","year":"2001"},{"key":"2020042304154226900_ehz486-B556","volume-title":"Patient-Centered Medicine - Transforming the Clinical Method","author":"Stewart","year":"2003","edition":"2nd ed"},{"key":"2020042304154226900_ehz486-B557","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/ije\/dyr029","article-title":"Type 2 diabetes incidence and socio-economic position: a systematic review and meta-analysis","volume":"40","author":"Agardh","year":"2011","journal-title":"Int J Epidemiol"},{"key":"2020042304154226900_ehz486-B558","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1161\/CIRCULATIONAHA.117.029652","article-title":"Socioeconomic status and cardiovascular outcomes: challenges and interventions","volume":"137","author":"Schultz","year":"2018","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B559","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/CIR.0000000000000579","article-title":"Health literacy and cardiovascular disease: fundamental relevance to primary and secondary prevention: a scientific statement from the American Heart Association","volume":"138","author":"Magnani","year":"2018","journal-title":"Circulation"},{"key":"2020042304154226900_ehz486-B560","first-page":"CD003417","article-title":"Group based training for self-management strategies in people with type 2 diabetes mellitus","volume":"2","author":"Deakin","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"2020042304154226900_ehz486-B561","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/1472-6963-12-213","article-title":"Group based diabetes self-management education compared to routine treatment for people with type 2 diabetes mellitus. A systematic review with meta-analysis","volume":"12","author":"Steinsbekk","year":"2012","journal-title":"BMC Health Serv Res"},{"key":"2020042304154226900_ehz486-B562","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/dme.13340","article-title":"Effectiveness of group-based self-management education for individuals with Type 2 diabetes: a systematic review with meta-analyses and meta-regression","volume":"34","author":"Odgers-Jewell","year":"2017","journal-title":"Diabet Med"},{"key":"2020042304154226900_ehz486-B563","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.diabres.2017.02.021","article-title":"Systematic review on the cost-effectiveness of self-management education programme for type 2 diabetes mellitus","volume":"127","author":"Lian","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"2020042304154226900_ehz486-B564","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.pcd.2017.10.004","article-title":"Effectiveness of individual strategies for the empowerment of patients with diabetes mellitus: a systematic review with meta-analysis","volume":"12","author":"Aquino","year":"2018","journal-title":"Prim Care Diabetes"},{"key":"2020042304154226900_ehz486-B565","first-page":"99","article-title":"Empowerment program for people with prediabetes: a randomized controlled trial","volume":"25","author":"Chen","year":"2017","journal-title":"J\u00a0Nurs Res"},{"key":"2020042304154226900_ehz486-B566","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12020-015-0775-7","article-title":"The role of patient education in the prevention and management of type 2 diabetes: an overview","volume":"53","author":"Coppola","year":"2016","journal-title":"Endocrine"},{"key":"2020042304154226900_ehz486-B567","first-page":"8493145","article-title":"The effectiveness of lifestyle adaptation for the prevention of prediabetes in adults: a systematic review","volume":"2017","author":"Kerrison","year":"2017","journal-title":"J\u00a0Diabetes Res"},{"key":"2020042304154226900_ehz486-B568","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.metabol.2014.10.018","article-title":"Effect of lifestyle intervention in patients with type 2 diabetes: a meta-analysis","volume":"64","author":"Chen","year":"2015","journal-title":"Metabolism"},{"key":"2020042304154226900_ehz486-B569","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"2020042304154226900_ehz486-B570","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1111\/jocn.13487","article-title":"An evaluation of the effectiveness of self-management interventions for people with type 2 diabetes after an acute coronary syndrome: a systematic review","volume":"26","author":"Tanash","year":"2017","journal-title":"J\u00a0Clin Nurs"},{"issue":"10","key":"2020042304154226900_ehz486-B571","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006404","article-title":"Benefits of Cardiac Rehabilitation on Cardiovascular Outcomes in Patients With Diabetes Mellitus After Percutaneous Coronary Intervention","volume":"6","author":"Jimenez-Navarro","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2020042304154226900_ehz486-B572","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/1479164117744490","article-title":"An analysis of barriers to entry of cardiac rehabilitation in patients with diabetes: using data from the National Audit of Cardiac Rehabilitation","volume":"15","author":"Harrison","year":"2018","journal-title":"Diab Vasc Dis Res"},{"key":"2020042304154226900_ehz486-B573","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ejcnurse.2011.06.008","article-title":"Person-centered care--ready for prime time","volume":"10","author":"Ekman","year":"2011","journal-title":"Eur J Cardiovasc Nurs"},{"key":"2020042304154226900_ehz486-B574","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.diabres.2015.10.021","article-title":"Glycemic load, exercise, and monitoring blood glucose (GEM): a paradigm shift in the treatment of type 2 diabetes mellitus","volume":"111","author":"Cox","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"key":"2020042304154226900_ehz486-B575","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.2196\/jmir.4112","article-title":"Overcoming clinical inertia: a randomized clinical trial of a telehealth remote monitoring intervention using paired glucose testing in adults with type 2 diabetes","volume":"17","author":"Greenwood","year":"2015","journal-title":"J\u00a0Med Internet Res"},{"key":"2020042304154226900_ehz486-B576","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/1745-6215-15-321","article-title":"Effect of guided self-determination youth intervention integrated into outpatient visits versus treatment as usual on glycemic control and life skills: a randomized clinical trial in adolescents with type 1 diabetes","volume":"15","author":"Husted","year":"2014","journal-title":"Trials"},{"key":"2020042304154226900_ehz486-B577","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1089\/dia.2008.0063","article-title":"Web-based collaborative care for type 1 diabetes: a pilot randomized trial","volume":"11","author":"McCarrier","year":"2009","journal-title":"Diabetes Technol Ther"},{"key":"2020042304154226900_ehz486-B578","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/j.1365-2648.2009.05040.x","article-title":"Instruments to tailor care of people with type 2 diabetes","volume":"65","author":"Sigurdardottir","year":"2009","journal-title":"J\u00a0Adv Nurs"},{"key":"2020042304154226900_ehz486-B579","first-page":"215","article-title":"A study on efficacy of empowerment training among diabetes patients","volume":"8","author":"Wu","year":"2011","journal-title":"Life Science J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/41\/2\/255\/33115788\/ehz486.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/41\/2\/255\/33115788\/ehz486.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T01:35:16Z","timestamp":1664242516000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/41\/2\/255\/5556890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,31]]},"references-count":579,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,8,31]]},"published-print":{"date-parts":[[2020,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehz486","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1,7]]},"published":{"date-parts":[[2019,8,31]]}}}